<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7076579/results/search/disease/results.xml">
  <result pre="London, England pmcid: 7076579 doi: 10.1177/1759720X2091264610.1177_1759720X20912646 : When Rheumatology and" exact="Infectious" post="Disease Come Together: Review Reactivation of hepatitis B virus"/>
  <result pre="England pmcid: 7076579 doi: 10.1177/1759720X2091264610.1177_1759720X20912646 : When Rheumatology and Infectious" exact="Disease" post="Come Together: Review Reactivation of hepatitis B virus infection"/>
  <result pre="When Rheumatology and Infectious Disease Come Together: Review Reactivation of" exact="hepatitis" post="B virus infection in rheumatic diseases: risk and management"/>
  <result pre="and Infectious Disease Come Together: Review Reactivation of hepatitis B" exact="virus infection" post="in rheumatic diseases: risk and management considerations KoutsianasChristos[], [],"/>
  <result pre="Infectious Disease Come Together: Review Reactivation of hepatitis B virus" exact="infection" post="in rheumatic diseases: risk and management considerations KoutsianasChristos[], [],"/>
  <result pre="Come Together: Review Reactivation of hepatitis B virus infection in" exact="rheumatic" post="diseases: risk and management considerations KoutsianasChristos[], [], ThomasKonstantinos[], https://orcid.org/0000-0003-2288-3863VassilopoulosDimitrios[],"/>
  <result pre="SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Abstract In patients with" exact="rheumatic" post="diseases undergoing immunosuppressive treatment, hepatitis B virus reactivation (HBVr)"/>
  <result pre="(https://us.sagepub.com/en-us/nam/open-access-at-sage). Abstract In patients with rheumatic diseases undergoing immunosuppressive treatment," exact="hepatitis" post="B virus reactivation (HBVr) has been long recognized as"/>
  <result pre="(i.e. Janus kinase inhibitors) acquiring licenses for a variety of" exact="rheumatic" post="diseases. The class-specific risk of these agents for HBVr"/>
  <result pre="setting of resolved HBV infection. Clinicians in the field of" exact="rheumatic" post="diseases should be tailoring their practice according to the"/>
  <result pre="the existing literature and provide practical advice on these issues." exact="hepatitis" post="B virus reactivation rheumatic disease screening biologics DMARD immunosuppression"/>
  <result pre="provide practical advice on these issues. hepatitis B virus reactivation" exact="rheumatic" post="disease screening biologics DMARD immunosuppression Introduction Hepatitis B virus"/>
  <result pre="practical advice on these issues. hepatitis B virus reactivation rheumatic" exact="disease" post="screening biologics DMARD immunosuppression Introduction Hepatitis B virus (HBV)"/>
  <result pre="B virus reactivation rheumatic disease screening biologics DMARD immunosuppression Introduction" exact="Hepatitis" post="B virus (HBV) infection still poses a significant worldwide"/>
  <result pre="disease screening biologics DMARD immunosuppression Introduction Hepatitis B virus (HBV)" exact="infection" post="still poses a significant worldwide morbidity and mortality burden,"/>
  <result pre="an efficacious vaccine and antiviral treatment. The global prevalence of" exact="chronic" post="HBV infection has been recently estimated at 3.61%,1 and,"/>
  <result pre="vaccine and antiviral treatment. The global prevalence of chronic HBV" exact="infection" post="has been recently estimated at 3.61%,1 and, although it"/>
  <result pre="2015.2 There is substantial geographical variance in the rates of" exact="chronic" post="HBV infection, which is highly endemic in the Western"/>
  <result pre="which is highly endemic in the Western Pacific (6.2%) and" exact="African" post="(6.1%) areas, but less common in Europe (1.6%) and"/>
  <result pre="studies suggest that the prevalence of HBV in patients with" exact="rheumatic" post="disease follows the pattern of the general population. Chronic"/>
  <result pre="suggest that the prevalence of HBV in patients with rheumatic" exact="disease" post="follows the pattern of the general population. Chronic HBV"/>
  <result pre="with rheumatic disease follows the pattern of the general population." exact="Chronic" post="HBV infection rates in rheumatoid arthritis (RA) and ankylosing"/>
  <result pre="disease follows the pattern of the general population. Chronic HBV" exact="infection" post="rates in rheumatoid arthritis (RA) and ankylosing spondylitis (AS)"/>
  <result pre="pattern of the general population. Chronic HBV infection rates in" exact="rheumatoid arthritis" post="(RA) and ankylosing spondylitis (AS) have been estimated at"/>
  <result pre="of the general population. Chronic HBV infection rates in rheumatoid" exact="arthritis" post="(RA) and ankylosing spondylitis (AS) have been estimated at"/>
  <result pre="population. Chronic HBV infection rates in rheumatoid arthritis (RA) and" exact="ankylosing spondylitis" post="(AS) have been estimated at 3.0% and 3.5%, respectively,"/>
  <result pre="Chronic HBV infection rates in rheumatoid arthritis (RA) and ankylosing" exact="spondylitis" post="(AS) have been estimated at 3.0% and 3.5%, respectively,"/>
  <result pre="been estimated at 3.0% and 3.5%, respectively, whereas resolved HBV" exact="infection" post="rate ranges between 13% and 50%.3–5 HBV is a"/>
  <result pre="that is transmitted via the parenteral route, and can cause" exact="acute" post="or chronic infection. The risk of chronicity is dependent"/>
  <result pre="is transmitted via the parenteral route, and can cause acute" exact="or chronic" post="infection. The risk of chronicity is dependent mainly on"/>
  <result pre="transmitted via the parenteral route, and can cause acute or" exact="chronic" post="infection. The risk of chronicity is dependent mainly on"/>
  <result pre="majority of infants (&amp;gt;90%) and only &amp;lt;5% of adults develop" exact="chronic" post="HBV infection after exposure. Distinguishing between acute, chronic, past"/>
  <result pre="infants (&amp;gt;90%) and only &amp;lt;5% of adults develop chronic HBV" exact="infection" post="after exposure. Distinguishing between acute, chronic, past (resolved), and"/>
  <result pre="after exposure. Distinguishing between acute, chronic, past (resolved), and occult" exact="infection" post="lies in HBV serological markers and measurement of serum"/>
  <result pre="HBV serology (adapted from Koutsianas and colleagues5). Nomenclature for HBV" exact="infection" post="based on biochemistry, serology and viral load Acute HBV"/>
  <result pre="colleagues5). Nomenclature for HBV infection based on biochemistry, serology and" exact="viral" post="load Acute HBV infection Chronic HBV infection Past infection"/>
  <result pre="for HBV infection based on biochemistry, serology and viral load" exact="Acute" post="HBV infection Chronic HBV infection Past infection Chronic hepatitis"/>
  <result pre="infection based on biochemistry, serology and viral load Acute HBV" exact="infection" post="Chronic HBV infection Past infection Chronic hepatitis Inactive carrier"/>
  <result pre="based on biochemistry, serology and viral load Acute HBV infection" exact="Chronic" post="HBV infection Past infection Chronic hepatitis Inactive carrier Resolved"/>
  <result pre="biochemistry, serology and viral load Acute HBV infection Chronic HBV" exact="infection" post="Past infection Chronic hepatitis Inactive carrier Resolved infection Occult"/>
  <result pre="and viral load Acute HBV infection Chronic HBV infection Past" exact="infection" post="Chronic hepatitis Inactive carrier Resolved infection Occult infection HBeAg"/>
  <result pre="viral load Acute HBV infection Chronic HBV infection Past infection" exact="Chronic" post="hepatitis Inactive carrier Resolved infection Occult infection HBeAg (+)"/>
  <result pre="load Acute HBV infection Chronic HBV infection Past infection Chronic" exact="hepatitis" post="Inactive carrier Resolved infection Occult infection HBeAg (+) HBeAg"/>
  <result pre="Chronic HBV infection Past infection Chronic hepatitis Inactive carrier Resolved" exact="infection" post="Occult infection HBeAg (+) HBeAg (−) HBsAg + +"/>
  <result pre="infection Past infection Chronic hepatitis Inactive carrier Resolved infection Occult" exact="infection" post="HBeAg (+) HBeAg (−) HBsAg + + + +"/>
  <result pre="Usually&amp;gt;2000 IU/mLb Undetectable Undetectable Detectable (low levels) ALT Markedly elevated" exact="Elevated" post="Elevated Normal Normal Normal aHBV-DNA levels are usually elevated,"/>
  <result pre="IU/mLb Undetectable Undetectable Detectable (low levels) ALT Markedly elevated Elevated" exact="Elevated" post="Normal Normal Normal aHBV-DNA levels are usually elevated, but"/>
  <result pre="Undetectable Undetectable Detectable (low levels) ALT Markedly elevated Elevated Elevated" exact="Normal" post="Normal Normal aHBV-DNA levels are usually elevated, but may"/>
  <result pre="Undetectable Detectable (low levels) ALT Markedly elevated Elevated Elevated Normal" exact="Normal" post="Normal aHBV-DNA levels are usually elevated, but may vary"/>
  <result pre="Detectable (low levels) ALT Markedly elevated Elevated Elevated Normal Normal" exact="Normal" post="aHBV-DNA levels are usually elevated, but may vary depending"/>
  <result pre="measurement. As HBV-related complications have been identified in patients with" exact="lower" post="HBV-DNA levels, it is important to interpret HBV-DNA taking"/>
  <result pre="interpret HBV-DNA taking into consideration other factors (age, duration, ALT," exact="disease" post="stage). ALT, alanine aminotransferase; anti-HBc, antibody against hepatitis B"/>
  <result pre="duration, ALT, disease stage). ALT, alanine aminotransferase; anti-HBc, antibody against" exact="hepatitis" post="B core antigen; anti-HBe, antibody against HBeAg; anti-HBs, antibody"/>
  <result pre="antigen; anti-HBe, antibody against HBeAg; anti-HBs, antibody against HBsAg; HBeAg," exact="hepatitis" post="B envelope antigen; HBsAg, hepatitis B surface antigen; HBV,"/>
  <result pre="anti-HBs, antibody against HBsAg; HBeAg, hepatitis B envelope antigen; HBsAg," exact="hepatitis" post="B surface antigen; HBV, hepatitis B virus; HBV-DNA, HBV-deoxyribonucleic"/>
  <result pre="hepatitis B envelope antigen; HBsAg, hepatitis B surface antigen; HBV," exact="hepatitis" post="B virus; HBV-DNA, HBV-deoxyribonucleic acid; PCR, polymerase chain reaction."/>
  <result pre="screening for HBV and interpretation of results. anti-HBc, antibody against" exact="hepatitis" post="B core antigen; anti-HBs, antibody against hepatitis B surface"/>
  <result pre="anti-HBc, antibody against hepatitis B core antigen; anti-HBs, antibody against" exact="hepatitis" post="B surface antigen; HBsAg, hepatitis B surface antigen; HBV,"/>
  <result pre="core antigen; anti-HBs, antibody against hepatitis B surface antigen; HBsAg," exact="hepatitis" post="B surface antigen; HBV, hepatitis B virus. HBV is"/>
  <result pre="hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; HBV," exact="hepatitis" post="B virus. HBV is unique in its ability to"/>
  <result pre="virus. HBV is unique in its ability to integrate its" exact="viral" post="genome in its host’s DNA by forming covalently closed"/>
  <result pre="and adaptive immunity. A strong immune response is associated with" exact="viral" post="clearance in acute HBV infection, but is also responsible"/>
  <result pre="A strong immune response is associated with viral clearance in" exact="acute" post="HBV infection, but is also responsible for hepatocyte damage"/>
  <result pre="hepatocyte damage and fibrosis in the immune active phases of" exact="chronic" post="HBV infection. Hepatitis B virus reactivation HBV reactivation (HBVr)"/>
  <result pre="fibrosis in the immune active phases of chronic HBV infection." exact="Hepatitis" post="B virus reactivation HBV reactivation (HBVr) is a well-recognized"/>
  <result pre="(HBVr) is a well-recognized complication of immunosuppressive treatment in cancer," exact="rheumatic" post="diseases, and organ transplantation.9 It typically occurs in patients"/>
  <result pre="diseases, and organ transplantation.9 It typically occurs in patients with" exact="chronic" post="HBV infection [Hepatitis B surface Antigen (HBsAg) positive], but,"/>
  <result pre="organ transplantation.9 It typically occurs in patients with chronic HBV" exact="infection" post="[Hepatitis B surface Antigen (HBsAg) positive], but, less commonly,"/>
  <result pre="it can complicate immunosuppressive treatment in patients with resolved HBV" exact="infection" post="[HBsAg negative/antibody against Hepatitis B core antigen (anti-HBc) positive]."/>
  <result pre="treatment in patients with resolved HBV infection [HBsAg negative/antibody against" exact="Hepatitis" post="B core antigen (anti-HBc) positive]. HBVr is usually defined"/>
  <result pre="(−)Anti-HBc (+) HBsAg (+) ALT, alanine aminotransferase; anti-HBc, antibody against" exact="hepatitis" post="B core antigen; HBsAg, hepatitis B surface antigen; HBV,"/>
  <result pre="alanine aminotransferase; anti-HBc, antibody against hepatitis B core antigen; HBsAg," exact="hepatitis" post="B surface antigen; HBV, hepatitis B virus. Table 3."/>
  <result pre="hepatitis B core antigen; HBsAg, hepatitis B surface antigen; HBV," exact="hepatitis" post="B virus. Table 3. Risk factors for HBV reactivation"/>
  <result pre="HBV reactivation (literature data).12–14 Host factors Male sexOlder ageCirrhosisType of" exact="disease" post="needing immunosuppression (lymphoma)Co-infection status (e.g. HCV, HIV, HDV) Virological"/>
  <result pre="main text for details) ALT, alanine aminotransferase; anti-HBc, antibody against" exact="hepatitis" post="B core antigen; HBeAg, hepatitis B envelope antigen; HBsAg,"/>
  <result pre="alanine aminotransferase; anti-HBc, antibody against hepatitis B core antigen; HBeAg," exact="hepatitis" post="B envelope antigen; HBsAg, hepatitis B surface antigen; HBV,"/>
  <result pre="hepatitis B core antigen; HBeAg, hepatitis B envelope antigen; HBsAg," exact="hepatitis" post="B surface antigen; HBV, hepatitis B virus; HBV-DNA, HBV-deoxyribonucleic"/>
  <result pre="hepatitis B envelope antigen; HBsAg, hepatitis B surface antigen; HBV," exact="hepatitis" post="B virus; HBV-DNA, HBV-deoxyribonucleic acid; HCV, hepatitis C virus;"/>
  <result pre="surface antigen; HBV, hepatitis B virus; HBV-DNA, HBV-deoxyribonucleic acid; HCV," exact="hepatitis" post="C virus; HDV, hepatitis D virus; HIV, human immunodeficiency"/>
  <result pre="B virus; HBV-DNA, HBV-deoxyribonucleic acid; HCV, hepatitis C virus; HDV," exact="hepatitis" post="D virus; HIV, human immunodeficiency virus. With the expected"/>
  <result pre="HCV, hepatitis C virus; HDV, hepatitis D virus; HIV, human" exact="immunodeficiency" post="virus. With the expected further increase in the use"/>
  <result pre="targeted synthetic agents [i.e. Janus kinase (JAK) inhibitors] in treating" exact="rheumatic" post="diseases, rheumatologists should be aware of the potential risk,"/>
  <result pre="with higher immunosuppressive potential are routinely used, usually for a" exact="short" post="period of time (months). These data need to be"/>
  <result pre="data need to be interpreted with caution when applied to" exact="rheumatic" post="diseases, where the potency of immunosuppression is lower and"/>
  <result pre="applied to rheumatic diseases, where the potency of immunosuppression is" exact="lower" post="and the duration of therapy longer (years). In a"/>
  <result pre="In a recent meta-analysis for the prevalence of HBVr in" exact="rheumatic" post="diseases being treated with conventional or biologic agents, the"/>
  <result pre="biologic agents, the pooled HBVr estimate was 1.4%, thus much" exact="lower" post="than the relevant estimation in hematology/oncology.16 In recent years,"/>
  <result pre="the type and duration of the immunosuppressive treatment used. The" exact="American" post="Gastroenterological Association (AGA) classified HBVr risk as low (&amp;lt;1%),"/>
  <result pre="agents and the long duration of biologic treatments, especially in" exact="rheumatic" post="diseases where there usually are no set stopping rules"/>
  <result pre="review the existing literature on HBVr risk in patients with" exact="rheumatic" post="diseases treated with different biologic and nonbiologic agents, and"/>
  <result pre="and management Glucocorticoids Glucocorticoid (GC) use in patients with HBV" exact="infection" post="was known to relate to HBVr as early as"/>
  <result pre="the HBV genome.17,19 There is robust literature evidence that even" exact="short" post="courses of more than moderate-dose GC treatment in chronic"/>
  <result pre="even short courses of more than moderate-dose GC treatment in" exact="chronic" post="HBV infection can lead to HBVr.17,20–22 Chemotherapy for chronically"/>
  <result pre="courses of more than moderate-dose GC treatment in chronic HBV" exact="infection" post="can lead to HBVr.17,20–22 Chemotherapy for chronically HBV-infected patients"/>
  <result pre="can lead to HBVr.17,20–22 Chemotherapy for chronically HBV-infected patients with" exact="lymphoma" post="was less likely to cause HBVr in 9 months if"/>
  <result pre="An HBVr incidence rate of 6.1% has been reported in" exact="chronic" post="HBV patients with asthma or chronic obstructive pulmonary disease"/>
  <result pre="of 6.1% has been reported in chronic HBV patients with" exact="asthma" post="or chronic obstructive pulmonary disease (COPD) receiving GCs. The"/>
  <result pre="6.1% has been reported in chronic HBV patients with asthma" exact="or chronic" post="obstructive pulmonary disease (COPD) receiving GCs. The risk was"/>
  <result pre="has been reported in chronic HBV patients with asthma or" exact="chronic" post="obstructive pulmonary disease (COPD) receiving GCs. The risk was"/>
  <result pre="reported in chronic HBV patients with asthma or chronic obstructive" exact="pulmonary disease" post="(COPD) receiving GCs. The risk was higher among patients"/>
  <result pre="in chronic HBV patients with asthma or chronic obstructive pulmonary" exact="disease" post="(COPD) receiving GCs. The risk was higher among patients"/>
  <result pre="chronic HBV patients with asthma or chronic obstructive pulmonary disease" exact="(COPD)" post="receiving GCs. The risk was higher among patients receiving"/>
  <result pre="(COPD) receiving GCs. The risk was higher among patients receiving" exact="systemic" post="GCs, especially when they were used continuously (for at"/>
  <result pre="3 months) and in medium to high (&amp;gt;20 mg/day) doses.24 Patients with" exact="chronic" post="HBV infection and rheumatic diseases are also at risk"/>
  <result pre="in medium to high (&amp;gt;20 mg/day) doses.24 Patients with chronic HBV" exact="infection" post="and rheumatic diseases are also at risk for HBVr"/>
  <result pre="to high (&amp;gt;20 mg/day) doses.24 Patients with chronic HBV infection and" exact="rheumatic" post="diseases are also at risk for HBVr and hepatic"/>
  <result pre="risk is higher depending on the patient’s HBV status (i.e." exact="chronic hepatitis" post="versus inactive carrier state), on the continuous oral GC"/>
  <result pre="is higher depending on the patient’s HBV status (i.e. chronic" exact="hepatitis" post="versus inactive carrier state), on the continuous oral GC"/>
  <result pre="IV GC pulse therapy in HBsAg positive patients, data are" exact="limited" post="and confounded by the concomitant use of other immunosuppressives"/>
  <result pre="regarding patients treated with IV GC pulses due to the" exact="absence of" post="data, but note that any GC dose given for"/>
  <result pre="resolved HBV infection, but certainly this risk seems to be" exact="lower" post="than in chronic HBV infection. In a retrospective Chinese"/>
  <result pre="but certainly this risk seems to be lower than in" exact="chronic" post="HBV infection. In a retrospective Chinese study of a"/>
  <result pre="negative/anti-HBc positive population treated with at least one dose of" exact="systemic" post="GCs for all indications, the incidence rate of HBsAg"/>
  <result pre="treatment duration for &amp;gt;4 weeks were independent risk factors for a" exact="hepatitis" post="flare but not for HBsAg seroreversion.31 The authors could"/>
  <result pre="not identify studies from geographical areas with less prevalent HBV" exact="infection" post="to confirm this relatively high HBVr rate. GC use"/>
  <result pre="high HBVr rate. GC use at the doses needed for" exact="adrenal insufficiency" post="has been reported to be safe, and does not"/>
  <result pre="it is also frequently used in the management of other" exact="rheumatic" post="diseases [spondyloarthropathies, systemic lupus erythematosus (SLE), vasculitis, myositis, scleroderma,"/>
  <result pre="frequently used in the management of other rheumatic diseases [spondyloarthropathies," exact="systemic" post="lupus erythematosus (SLE), vasculitis, myositis, scleroderma, etc.]. MTX is"/>
  <result pre="used in the management of other rheumatic diseases [spondyloarthropathies, systemic" exact="lupus erythematosus" post="(SLE), vasculitis, myositis, scleroderma, etc.]. MTX is associated with"/>
  <result pre="(SLE), vasculitis, myositis, scleroderma, etc.]. MTX is associated with direct" exact="acute" post="(hepatitis) and more rarely with chronic (fibrosis) hepatotoxicity. With"/>
  <result pre="is associated with direct acute (hepatitis) and more rarely with" exact="chronic" post="(fibrosis) hepatotoxicity. With appropriate pre-treatment screening and regular monitoring,"/>
  <result pre="today. In a retrospective analysis of a Thai population with" exact="rheumatic" post="diseases being treated with MTX for an average of"/>
  <result pre="for an average of 9.9 years, no cases of HBVr or" exact="hepatitis" post="flares were identified,34 whereas in a similar data analysis"/>
  <result pre="analysis from a national Taiwanese health database, no increased risk" exact="of liver" post="cirrhosis was seen (compared with non-users of MTX).35 With"/>
  <result pre="from a national Taiwanese health database, no increased risk of" exact="liver cirrhosis" post="was seen (compared with non-users of MTX).35 With regards"/>
  <result pre="a national Taiwanese health database, no increased risk of liver" exact="cirrhosis" post="was seen (compared with non-users of MTX).35 With regards"/>
  <result pre="these agents to HBVr is unclear.36 Similarly, among patients with" exact="rheumatic" post="disease and resolved HBV infection taking part in a"/>
  <result pre="agents to HBVr is unclear.36 Similarly, among patients with rheumatic" exact="disease" post="and resolved HBV infection taking part in a large"/>
  <result pre="unclear.36 Similarly, among patients with rheumatic disease and resolved HBV" exact="infection" post="taking part in a large prospective multicenter study, use"/>
  <result pre="as low risk treatment for HBVr in patients with both" exact="chronic" post="and resolved HBV infection. Nevertheless, for those agents with"/>
  <result pre="prednisone regimen (1 mg/kg daily) versus MMF (500–1000 mg twice daily) and" exact="lower" post="prednisone dose (0.5 mg/kg daily) in HBsAg-positive patients with idiopathic"/>
  <result pre="lower prednisone dose (0.5 mg/kg daily) in HBsAg-positive patients with idiopathic" exact="nephrotic syndrome" post="and ‘undetectable’ HBV-DNA (&amp;lt;1.000 copies/mL).42 HBVr (defined as HBV-DNA"/>
  <result pre="prednisone dose (0.5 mg/kg daily) in HBsAg-positive patients with idiopathic nephrotic" exact="syndrome" post="and ‘undetectable’ HBV-DNA (&amp;lt;1.000 copies/mL).42 HBVr (defined as HBV-DNA"/>
  <result pre="of HBV. In a retrospective study of SLE patients with" exact="chronic" post="or resolved HBV infection from Taiwan, MMF was not"/>
  <result pre="retrospective study of SLE patients with chronic or resolved HBV" exact="infection" post="from Taiwan, MMF was not found to be among"/>
  <result pre="risk for HBVr, similar to that of other conventional synthetic" exact="disease" post="modifying antirheumatic drugs (csDMARDs). Cyclophosphamide Cyclophosphamide (CYC)-containing regimens have"/>
  <result pre="resulting state of immunosuppression cannot be compared with that of" exact="rheumatic" post="patients treated with CYC. For the majority of circumstances"/>
  <result pre="of remission in patients with severe manifestations of SLE and" exact="systemic" post="vasculitides, such as AAV, polyarteritis nodosa (PAN), and CNS"/>
  <result pre="severe manifestations of SLE and systemic vasculitides, such as AAV," exact="polyarteritis nodosa" post="(PAN), and CNS vasculitis. Whereas things are more-or-less clear-cut"/>
  <result pre="CNS vasculitis. Whereas things are more-or-less clear-cut with patients with" exact="chronic" post="HBV infection being candidates for prophylactic antiviral treatment, data"/>
  <result pre="Whereas things are more-or-less clear-cut with patients with chronic HBV" exact="infection" post="being candidates for prophylactic antiviral treatment, data on the"/>
  <result pre="candidates for prophylactic antiviral treatment, data on the management of" exact="rheumatic" post="patients with resolved HBV infection planned to be treated"/>
  <result pre="data on the management of rheumatic patients with resolved HBV" exact="infection" post="planned to be treated with CYC-containing regimens remain scarce."/>
  <result pre="CYC-containing regimens remain scarce. In a large cohort of 2054" exact="rheumatic" post="patients,44 (anti-HBc positive: 5%, n = 183 with vasculitis), eight cases"/>
  <result pre="were recorded, but only one occurred in a patient with" exact="granulomatosis with polyangiitis" post="(GPA) treated with CYC. The kinetics and outcomes of"/>
  <result pre="with CYC. The kinetics and outcomes of HBVr in various" exact="immune-mediated inflammatory diseases" post="from a wide spectrum of medical specialties were described"/>
  <result pre="study combining physician-collected and published patients.45 The authors included a" exact="total" post="of 138 HBV-infected patients, most with chronic HBV infection"/>
  <result pre="authors included a total of 138 HBV-infected patients, most with" exact="chronic" post="HBV infection (n = 99, 72%); among them, 11 (8%) had"/>
  <result pre="a total of 138 HBV-infected patients, most with chronic HBV" exact="infection" post="(n = 99, 72%); among them, 11 (8%) had been treated"/>
  <result pre="HBVr occurred earlier than that associated with rituximab (RTX) or" exact="tumor" post="necrosis factor inhibitors (TNFi) (8 versus 13 versus 26 weeks,"/>
  <result pre="were treated with GCs and various immunosuppressives (including CYC) with" exact="chronic" post="(n = 38) or resolved (n = 157) HBV infection.43 Among 34 patients"/>
  <result pre="(n = 38) or resolved (n = 157) HBV infection.43 Among 34 patients with" exact="chronic" post="HBV infection not on antiviral prophylaxis, HBVr occurred in"/>
  <result pre="resolved (n = 157) HBV infection.43 Among 34 patients with chronic HBV" exact="infection" post="not on antiviral prophylaxis, HBVr occurred in 15 (44%),"/>
  <result pre="(44%), whereas in contrast, only 3 (1.9%) patients with resolved" exact="infection" post="experienced HBsAg seroreversion. However, in multivariate analysis, CYC was"/>
  <result pre="was an average prednisolone daily dose of &amp;gt;5 mg. From these" exact="limited" post="data, it appears that the risk for HBVr in"/>
  <result pre="patients, while the respective risk in patients with resolved HBV" exact="infection" post="is rather low. Prophylactic antiviral prophylaxis should be used"/>
  <result pre="not support universal antiviral protection for patients with resolved HBV" exact="infection" post="prior to induction of remission with CYC-containing regimens. Biologic"/>
  <result pre="drugs TNFi TNF inhibition has revolutionized the treatment of several" exact="rheumatic" post="diseases since the late 1990s. When it comes to"/>
  <result pre="TNFα neutralization may favor HBVr.46 The risk of HBVr in" exact="chronic" post="HBV infection patients receiving TNFi has been identified and"/>
  <result pre="may favor HBVr.46 The risk of HBVr in chronic HBV" exact="infection" post="patients receiving TNFi has been identified and is well"/>
  <result pre="prophylaxis range between 7.1% and 75% in the setting of" exact="rheumatic" post="diseases.25,47–54 Most HBVr cases were associated with a hepatitis"/>
  <result pre="of rheumatic diseases.25,47–54 Most HBVr cases were associated with a" exact="hepatitis" post="flare and in their majority they appeared within the"/>
  <result pre="contrary, it seems that the HBVr risk in resolved HBV" exact="infection" post="patients treated with TNF inhibitors is significantly lower.47–49,52,55,56 In"/>
  <result pre="In a recent meta-analysis of 468 published HBsAg negative/anti-HBc positive" exact="rheumatic" post="patients treated with TNFi, Lee and colleagues reported an"/>
  <result pre="no cases of HBVr were found among 146 resolved HBV" exact="infection" post="patients treated with TNFi for a mean period of"/>
  <result pre="could be due to different states of the underlying HBV" exact="infection" post="(occult versus resolved) or due to different HBV strains."/>
  <result pre="the basis of these data, TNF inhibition in patients with" exact="chronic" post="HBV infection (HBsAg+) carries a significant HBVr risk and"/>
  <result pre="of these data, TNF inhibition in patients with chronic HBV" exact="infection" post="(HBsAg+) carries a significant HBVr risk and it is"/>
  <result pre="leading to B-cell depletion. RTX has been used for various" exact="rheumatic" post="diseases including RA, AAV, cryoglobulinemic vasculitis, and off-label for"/>
  <result pre="studies looking into the benefit of using antiviral prophylaxis in" exact="chronic" post="HBV infection patients receiving RTX-containing regimens, the HBVr rate"/>
  <result pre="into the benefit of using antiviral prophylaxis in chronic HBV" exact="infection" post="patients receiving RTX-containing regimens, the HBVr rate was as"/>
  <result pre="use of lamivudine or entecavir. 63–65 In the setting of" exact="rheumatic" post="diseases, the available HBVr data for HBsAg-positive patients receiving"/>
  <result pre="there is robust data to support that RTX use in" exact="chronic" post="HBV infection is associated with very high HBVr rates"/>
  <result pre="robust data to support that RTX use in chronic HBV" exact="infection" post="is associated with very high HBVr rates (30–60%)17,33 and"/>
  <result pre="warranted. There is also evidence that, in the setting of" exact="rheumatic" post="disease, the duration of immunosuppression should be taken into"/>
  <result pre="However, in prospective or retrospective studies with patients suffering with" exact="rheumatic" post="diseases, the rate of HBVr under RTX therapy was"/>
  <result pre="diseases, the rate of HBVr under RTX therapy was much" exact="lower" post="(6/266 patients or 2%).58,72–76 Interestingly, the majority of reported"/>
  <result pre="controversy, the authors believe that in patients with resolved HBV" exact="infection" post="and undetectable baseline serum HBV-DNA, serial monitoring of aminotransferases,"/>
  <result pre="antigen-presenting cell. The agent has been approved for RA and" exact="psoriatic arthritis," post="and there are ongoing trials for other rheumatic diseases"/>
  <result pre="and psoriatic arthritis, and there are ongoing trials for other" exact="rheumatic" post="diseases (giant cell arteritis, polymyalgia rheumatica, myositis). The HBVr"/>
  <result pre="are ongoing trials for other rheumatic diseases (giant cell arteritis," exact="polymyalgia rheumatica," post="myositis). The HBVr risk for chronically infected HBV patients"/>
  <result pre="on 72 RA patients treated with ABA who had either" exact="chronic" post="or resolved HBV infection.78 All of the chronically infected"/>
  <result pre="a recently studied Japanese cohort were reported on resolved HBV" exact="infection" post="patients treated with ABA (total n = 29, 10.3%).81 In another"/>
  <result pre="10.3%).81 In another study, among 24 patients with resolved HBV" exact="infection" post="on ABA treatment, three cases of HBVr were reported"/>
  <result pre="(12.5%),37 but these were mild elevations of HBV-DNA without overt" exact="hepatitis" post="and without the need to use antivirals. Reassuringly, no"/>
  <result pre="no HBVr cases were observed among the nine resolved HBV" exact="infection" post="patients treated with ABA in the prospective trial by"/>
  <result pre="ABA since its approval, cases of HBVr in resolved HBV" exact="infection" post="appear to be rare, especially in geographical areas with"/>
  <result pre="infection appear to be rare, especially in geographical areas with" exact="lower" post="prevalence, such as Europe and the United States. Taken"/>
  <result pre="these data would suggest that, in ABA-treated HBV patients with" exact="rheumatic" post="disease, there is a need for antiviral prophylaxis in"/>
  <result pre="rheumatic disease, there is a need for antiviral prophylaxis in" exact="chronic" post="HBV infection, but close monitoring in resolved HBV infection"/>
  <result pre="in chronic HBV infection, but close monitoring in resolved HBV" exact="infection" post="seems to be a safe alternative. Interleukin-6 inhibitors Inhibition"/>
  <result pre="provides a new mechanism of action for the treatment of" exact="rheumatic" post="disease, and two agents have been approved for use"/>
  <result pre="two agents have been approved for use in RA and" exact="systemic" post="Juvenile Idiopathic Arthritis (sJIA) (tocilizumab-TCZ, sarilumab) and giant cell"/>
  <result pre="agents have been approved for use in RA and systemic" exact="Juvenile" post="Idiopathic Arthritis (sJIA) (tocilizumab-TCZ, sarilumab) and giant cell arteritis"/>
  <result pre="have been approved for use in RA and systemic Juvenile" exact="Idiopathic" post="Arthritis (sJIA) (tocilizumab-TCZ, sarilumab) and giant cell arteritis (GCA;"/>
  <result pre="been approved for use in RA and systemic Juvenile Idiopathic" exact="Arthritis" post="(sJIA) (tocilizumab-TCZ, sarilumab) and giant cell arteritis (GCA; tocilizumab)"/>
  <result pre="RA and systemic Juvenile Idiopathic Arthritis (sJIA) (tocilizumab-TCZ, sarilumab) and" exact="giant cell arteritis" post="(GCA; tocilizumab) with several others being investigated. Most of"/>
  <result pre="that HBVr can occur with TCZ therapy in patients with" exact="chronic" post="HBV infection without antiviral prophylaxis.25,83–86 In all published data,"/>
  <result pre="can occur with TCZ therapy in patients with chronic HBV" exact="infection" post="without antiviral prophylaxis.25,83–86 In all published data, the use"/>
  <result pre="the use of antivirals prevented HBVr in this setting. In" exact="rheumatic" post="patients with resolved infection, HBVr is rare,58,87 and has"/>
  <result pre="rare,58,87 and has been reported only in the form of" exact="transient" post="HBV viremia.37,88 Similarly to ABA and TNFi, antiviral prophylaxis"/>
  <result pre="inhibitors have recently been approved for the treatment of psoriasis," exact="psoriatic arthritis," post="and axial spondyloarthropathy. As patients with HBV infection were"/>
  <result pre="psoriasis, psoriatic arthritis, and axial spondyloarthropathy. As patients with HBV" exact="infection" post="were excluded from the initial controlled clinical trials for"/>
  <result pre="multicenter prospective cohort study of 49 Taiwanese patients with either" exact="chronic" post="or resolved HBV infection. Among those with chronic HBV"/>
  <result pre="with either chronic or resolved HBV infection. Among those with" exact="chronic" post="HBV infection who did not receive antiviral prophylaxis, 27%"/>
  <result pre="chronic or resolved HBV infection. Among those with chronic HBV" exact="infection" post="who did not receive antiviral prophylaxis, 27% (6/22) developed"/>
  <result pre="receive antiviral prophylaxis, 27% (6/22) developed virological HBVr without a" exact="hepatitis" post="flare, while the respective rate of virological HBVr in"/>
  <result pre="respective rate of virological HBVr in those with resolved HBV" exact="infection" post="was 4% (1/24).95 In the absence of solid data"/>
  <result pre="those with resolved HBV infection was 4% (1/24).95 In the" exact="absence of" post="solid data showing that IL-17A inhibition is associated with"/>
  <result pre="bind to their receptors. It has been approved for psoriasis," exact="psoriatic arthritis," post="and inflammatory bowel disease (Crohn’s disease, ulcerative colitis). Several"/>
  <result pre="receptors. It has been approved for psoriasis, psoriatic arthritis, and" exact="inflammatory bowel disease" post="(Crohn’s disease, ulcerative colitis). Several case reports and two"/>
  <result pre="It has been approved for psoriasis, psoriatic arthritis, and inflammatory" exact="bowel" post="disease (Crohn’s disease, ulcerative colitis). Several case reports and"/>
  <result pre="has been approved for psoriasis, psoriatic arthritis, and inflammatory bowel" exact="disease" post="(Crohn’s disease, ulcerative colitis). Several case reports and two"/>
  <result pre="treated with ustekinumab. In a single-center Taiwanese retrospective cohort,96 11" exact="chronic" post="HBV and 3 resolved HBV infection patients with psoriasis"/>
  <result pre="Taiwanese retrospective cohort,96 11 chronic HBV and 3 resolved HBV" exact="infection" post="patients with psoriasis received ustekinumab. HBVr was observed in"/>
  <result pre="11 chronic HBV and 3 resolved HBV infection patients with" exact="psoriasis" post="received ustekinumab. HBVr was observed in two of the"/>
  <result pre="received ustekinumab. HBVr was observed in two of the seven" exact="chronic" post="HBV infection patients who did not receive antiviral prophylaxis;"/>
  <result pre="HBVr was observed in two of the seven chronic HBV" exact="infection" post="patients who did not receive antiviral prophylaxis; in both"/>
  <result pre="a similar Asian study by Ting and colleagues of 54" exact="psoriasis" post="patients treated with ustekinumab,97 the rate of HBVr was"/>
  <result pre="risankizumab, and tildrakizumab have been approved for the treatment of" exact="psoriasis" post="and are currently under investigation for psoriatic arthritis. No"/>
  <result pre="the treatment of psoriasis and are currently under investigation for" exact="psoriatic arthritis." post="No literature data on their use in the setting"/>
  <result pre="literature data on their use in the setting of HBV" exact="infection" post="are available and, thus, no relevant recommendations exist. csDMARD"/>
  <result pre="csDMARD and biologic disease-modifying antirheumatic drug (bDMARD) combination treatment in" exact="rheumatic" post="patients carries higher risk for HBVr compared with bDMARD"/>
  <result pre="recently introduced into daily clinical practice for treatment of RA," exact="psoriatic arthritis," post="and ulcerative colitis. JAK inhibitors have a unique mode"/>
  <result pre="daily clinical practice for treatment of RA, psoriatic arthritis, and" exact="ulcerative colitis." post="JAK inhibitors have a unique mode of action, inhibiting"/>
  <result pre="and upadacitinib), with another currently under investigation (filgotinib). As for" exact="psoriatic arthritis," post="tofacitinib is the only JAK inhibitor currently approved for"/>
  <result pre="these agents’ pivotal clinical trials excluded patients with evidence of" exact="chronic" post="or resolved HBV infection. Two recent studies attempted to"/>
  <result pre="of 116 tofacitinib-treated RA patients from Taiwan, 6 (5%) had" exact="chronic" post="and 75 (65%) resolved HBV infection.99 Two of the"/>
  <result pre="the effect of baricitinib in RA patients with past HBV" exact="infection" post="in a post hoc analysis of baricitinib clinical trials.100"/>
  <result pre="included 269 patients, 255 of whom were anti-HBc positive/antibody against" exact="hepatitis" post="B surface antigen (anti-HBs) positive and 14 anti-HBc positive/anti-HBs"/>
  <result pre="group, seven (3%) patients had detectable baseline HBV DNA (median" exact="viral" post="load 256 IU/mL), while among the latter group, one (7%)"/>
  <result pre="among the latter group, one (7%) had marginally detectable HBV" exact="viral" post="load (36 IU/mL). From the total of eight patients with"/>
  <result pre="(7%) had marginally detectable HBV viral load (36 IU/mL). From the" exact="total" post="of eight patients with detectable baseline HBV DNA, half"/>
  <result pre="In a significant proportion (73–84%) of patients with resolved HBV" exact="infection" post="(HBsAg negative/anti-HBc positive), circulating anti-HBs antibodies can be detected"/>
  <result pre="role of anti-HBs levels in HBVr risk of patients with" exact="hematological malignancy," post="which found that the presence of detectable anti-HBs reduced"/>
  <result pre="reduced HBVr [pooled odds ratio (OR) = 0.21], even in patients with" exact="lymphoma" post="receiving RTX chemotherapy.105 Similar data have been reported in"/>
  <result pre="lymphoma receiving RTX chemotherapy.105 Similar data have been reported in" exact="rheumatic" post="patients with resolved HBV infection treated with different immunosuppressives"/>
  <result pre="data have been reported in rheumatic patients with resolved HBV" exact="infection" post="treated with different immunosuppressives and prospective studies support the"/>
  <result pre="predictive value of anti-HBs. Over a period of 4 years, 380" exact="rheumatic" post="patients on biologic therapy from a single Chinese center"/>
  <result pre="no HBVr cases in the ‘high’ group, whereas cases of" exact="transient" post="HBV viremia were seen in the both the ‘low’"/>
  <result pre="and ‘negative’ group (4.7/100 person-years).106 Among 1042 Japanese patients with" exact="rheumatic" post="diseases and resolved HBV infection who received both conventional"/>
  <result pre="Among 1042 Japanese patients with rheumatic diseases and resolved HBV" exact="infection" post="who received both conventional and biological treatments, HBVr incidence"/>
  <result pre="meta-analysis of HBVr in studies of patients with resolved HBV" exact="infection" post="from all medical fields showed that the total pooled"/>
  <result pre="resolved HBV infection from all medical fields showed that the" exact="total" post="pooled rate of HBV reactivation was lower in patients"/>
  <result pre="showed that the total pooled rate of HBV reactivation was" exact="lower" post="in patients with positive anti-HBs (5.2% versus 17.0%; RR:"/>
  <result pre="positivity when high risk treatments are used. Nevertheless, in the" exact="absence of" post="prospective data from randomized trials showing that patients with"/>
  <result pre="and management Screening The valued benefit of screening for HBV" exact="infection" post="prior commencing immunosuppressive treatment has been established in several"/>
  <result pre="unable to identify similar studies assessing HBV screening cost-effectiveness in" exact="rheumatic" post="patients prior to immunosuppression. Given the increased risk of"/>
  <result pre="the serological screening markers (HBsAg, anti-HBc) as suggested by recent" exact="American" post="Association for the Study of Liver Diseases (AASLD) and"/>
  <result pre="as suggested by recent American Association for the Study of" exact="Liver Diseases" post="(AASLD) and European Association for the Study of the"/>
  <result pre="suggested by recent American Association for the Study of Liver" exact="Diseases" post="(AASLD) and European Association for the Study of the"/>
  <result pre="initial or booster vaccination, but also cases of occult HBV" exact="infection" post="in anti-HBs positive patients that have not been vaccinated"/>
  <result pre="Vaccination still remains the most effective intervention for prevention of" exact="acute" post="and chronic HBV infection. The available vaccine containing recombinant"/>
  <result pre="remains the most effective intervention for prevention of acute and" exact="chronic" post="HBV infection. The available vaccine containing recombinant HBsAg shows"/>
  <result pre="HBsAg, anti-HBc, and anti-HBs (Figure 1) is capable of identifying" exact="rheumatic" post="patients not exposed to HBV [HBsAg/anti-HBc/anti-HBs(−)], and a complete"/>
  <result pre="identifying rheumatic patients not exposed to HBV [HBsAg/anti-HBc/anti-HBs(−)], and a" exact="complete" post="series of vaccination should be offered to those at"/>
  <result pre="according to their occupation, medical status, or sexual behavior. The" exact="complete" post="vaccination schedule with the recombinant HBsAg vaccine consists of"/>
  <result pre="on the efficacy and safety of this novel vaccine in" exact="rheumatic" post="patients are lacking. Management The management of HBVr (Figure"/>
  <result pre="Figure 2. Suggested algorithm for the management of HBVr in" exact="rheumatic" post="diseases. *In certain cases, close monitoring without antiviral therapy"/>
  <result pre="See text for details. ALT, alanine aminotransferase; anti-HBc, antibody against" exact="Hepatitis" post="B core antigen; anti-HBs, antibody against HBsAg; ETV, entecavir;"/>
  <result pre="B core antigen; anti-HBs, antibody against HBsAg; ETV, entecavir; HBsAg," exact="hepatitis" post="B surface antigen; HBV-DNA, HBV-deoxyribonucleic acid; HBVr, hepatitis B"/>
  <result pre="entecavir; HBsAg, hepatitis B surface antigen; HBV-DNA, HBV-deoxyribonucleic acid; HBVr," exact="hepatitis" post="B virus reactivation; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil"/>
  <result pre="of HBVr stratified per HBV status and agent used. Medication" exact="Chronic" post="HBV infection[HBsAg (+)] Resolved HBV infection[HBsAg (−) / anti-HBc"/>
  <result pre="JAK inhibitors Moderate Low ABA, Abatacept ; anti-HBc, antibody against" exact="Hepatitis" post="B core antigen; AZA, azathioprine; CYC, Cyclophosphamide; GC, glucocorticoids;"/>
  <result pre="B core antigen; AZA, azathioprine; CYC, Cyclophosphamide; GC, glucocorticoids; HBsAg," exact="Hepatitis" post="B surface antigen; HCQ, hydroxychloroquine; IL, interleukin; JAK, Janus"/>
  <result pre="leflunomide; MMF, mycophenolate mofetil; MTX, methotrexate; RTX, Rituximab ; TNFi," exact="tumor" post="necrosis factor inhibitors. Patients who are at moderate or"/>
  <result pre="treatment. Unlike in the oncology field, in the setting of" exact="rheumatic" post="disease, immunosuppressive treatment is usually used for prolonged periods"/>
  <result pre="Thus, there is need for enduring and potent control of" exact="viral" post="replication with negligible drug resistance. Given lamivudine’s low genetic"/>
  <result pre="commencing antiviral prophylaxis, especially in the setting of high baseline" exact="viral" post="loads, is 1–2 weeks before starting immunosuppressive treatment.15 If"/>
  <result pre="decision for stopping NAs when they are used for treating" exact="chronic hepatitis" post="B rather than for prophylaxis of reactivation.10,11 For patients"/>
  <result pre="for stopping NAs when they are used for treating chronic" exact="hepatitis" post="B rather than for prophylaxis of reactivation.10,11 For patients"/>
  <result pre="immunosuppression, especially if this is B-cell depleting treatment.113 Patients with" exact="chronic" post="HBV infection (HBsAg+) form the group with the highest"/>
  <result pre="if this is B-cell depleting treatment.113 Patients with chronic HBV" exact="infection" post="(HBsAg+) form the group with the highest HBVr risk."/>
  <result pre="taken after consulting a specialist with experience in treating HBV" exact="infection" post="(gastroenterologist, hepatologist, infectious disease specialist, etc.). In chronic active"/>
  <result pre="a specialist with experience in treating HBV infection (gastroenterologist, hepatologist," exact="infectious disease" post="specialist, etc.). In chronic active hepatitis B (elevated ALT"/>
  <result pre="specialist with experience in treating HBV infection (gastroenterologist, hepatologist, infectious" exact="disease" post="specialist, etc.). In chronic active hepatitis B (elevated ALT"/>
  <result pre="treating HBV infection (gastroenterologist, hepatologist, infectious disease specialist, etc.). In" exact="chronic" post="active hepatitis B (elevated ALT and HBV DNA levels,"/>
  <result pre="infection (gastroenterologist, hepatologist, infectious disease specialist, etc.). In chronic active" exact="hepatitis" post="B (elevated ALT and HBV DNA levels, or at"/>
  <result pre="at least detectable HBV DNA levels.10,11 Taking into account the" exact="chronic" post="nature of immunosuppression in most rheumatic patients, the unknown"/>
  <result pre="Taking into account the chronic nature of immunosuppression in most" exact="rheumatic" post="patients, the unknown real risk conferred with these agents"/>
  <result pre="antiviral therapy with the newer antivirals (as for patients with" exact="chronic hepatitis" post="B). In individual patients (i.e. those scheduled for short"/>
  <result pre="therapy with the newer antivirals (as for patients with chronic" exact="hepatitis" post="B). In individual patients (i.e. those scheduled for short"/>
  <result pre="chronic hepatitis B). In individual patients (i.e. those scheduled for" exact="short" post="term GCs: &amp;lt;1 month or treated with low risk nonbiologics"/>
  <result pre="with an HBV specialist. The issue of antiviral prophylaxis in" exact="rheumatic" post="patients with resolved HBV infection (HBsAg+, Anti-HBc–) treated with"/>
  <result pre="issue of antiviral prophylaxis in rheumatic patients with resolved HBV" exact="infection" post="(HBsAg+, Anti-HBc–) treated with immunosuppressives remains currently the most"/>
  <result pre="controversial. The discrepancies in the literature relate to the underlying" exact="disease" post="indication (hemato-oncology versus rheumatic) and to the geographical area"/>
  <result pre="For example, a recent meta-analysis of HBVr in resolved HBV" exact="infection" post="patients found that the pooled HBVr rates were much"/>
  <result pre="infection patients found that the pooled HBVr rates were much" exact="lower" post="in non-hematological (3.6%) versus hematological (10.9%) diseases.107 In the"/>
  <result pre="divergence in HBV prevalence, variance in host immune responses, different" exact="viral" post="genotypes and inconsistent monitoring intervals. There is general agreement"/>
  <result pre="genotypes and inconsistent monitoring intervals. There is general agreement that" exact="rheumatic" post="patients treated with non-biologics, as well as biologics other"/>
  <result pre="agents like RTX, prophylactic antiviral therapy is also necessary.10,11 For" exact="rheumatic" post="patients treated with RTX, such prophylactic antiviral therapy is"/>
  <result pre="experience with the use of RTX in large populations of" exact="rheumatic" post="patients with resolved infection (ranging from 5% to 50%"/>
  <result pre="of RTX in large populations of rheumatic patients with resolved" exact="infection" post="(ranging from 5% to 50% in the general population),"/>
  <result pre="with oral antivirals as described above. Summary In patients with" exact="rheumatic" post="disease under immunosuppressive treatment and HBV infection, HBVr is"/>
  <result pre="oral antivirals as described above. Summary In patients with rheumatic" exact="disease" post="under immunosuppressive treatment and HBV infection, HBVr is a"/>
  <result pre="need for prophylaxis in certain risk groups, the optimal frequency" exact="of liver" post="function and viral load monitoring and the potential use"/>
  <result pre="certain risk groups, the optimal frequency of liver function and" exact="viral" post="load monitoring and the potential use of alternative biomarkers"/>
  <result pre="https://orcid.org/0000-0003-2288-3863 References References 1SchweitzerAHornJMikolajczykRT, et al.Estimations of worldwide prevalence of" exact="chronic hepatitis" post="B virus infection: a systematic review of data published"/>
  <result pre="References References 1SchweitzerAHornJMikolajczykRT, et al.Estimations of worldwide prevalence of chronic" exact="hepatitis" post="B virus infection: a systematic review of data published"/>
  <result pre="and 2013. Lancet2015; 386: 1546–1555.26231459 2collab: World Health Organisation. Global" exact="hepatitis" post="report, 2017Geneva: World Health Organization, 2017. 3DougadosMSoubrierMAntunezA, et al.Prevalence"/>
  <result pre="World Health Organization, 2017. 3DougadosMSoubrierMAntunezA, et al.Prevalence of comorbidities in" exact="rheumatoid arthritis" post="and evaluation of their monitoring: results of an international,"/>
  <result pre="Health Organization, 2017. 3DougadosMSoubrierMAntunezA, et al.Prevalence of comorbidities in rheumatoid" exact="arthritis" post="and evaluation of their monitoring: results of an international,"/>
  <result pre="study. Ann Rheum Dis2016; 75: 1016–1023.26489703 5KoutsianasCThomasKVassilopoulosDHepatitis B reactivation in" exact="rheumatic" post="diseases: screening and prevention. Rheum Dis Clin North Am2017;"/>
  <result pre="biologic agents. Expert Rev Clin Pharmacol2016; 2433: 1–11. 7VassilopoulosDCalabreseLHManagement of" exact="rheumatic" post="disease with comorbid HBV or HCV infection. Nat Rev"/>
  <result pre="agents. Expert Rev Clin Pharmacol2016; 2433: 1–11. 7VassilopoulosDCalabreseLHManagement of rheumatic" exact="disease" post="with comorbid HBV or HCV infection. Nat Rev Rheumatol2012;"/>
  <result pre="HCV infection. Nat Rev Rheumatol2012; 8: 348–357.22565315 8SetoWKLoYRPawlotskyJM, et al.Chronic" exact="hepatitis" post="B virus infection. Lancet2018; 392: 2313–2324.30496122 9HoofnagleJHReactivation of hepatitis"/>
  <result pre="Nat Rev Rheumatol2012; 8: 348–357.22565315 8SetoWKLoYRPawlotskyJM, et al.Chronic hepatitis B" exact="virus infection." post="Lancet2018; 392: 2313–2324.30496122 9HoofnagleJHReactivation of hepatitis B. Hepatology2009; 49:"/>
  <result pre="al.Chronic hepatitis B virus infection. Lancet2018; 392: 2313–2324.30496122 9HoofnagleJHReactivation of" exact="hepatitis" post="B. Hepatology2009; 49: S156–S165.19399803 10TerraultNALokASFMcMahonBJ, et al.Update on prevention,"/>
  <result pre="S156–S165.19399803 10TerraultNALokASFMcMahonBJ, et al.Update on prevention, diagnosis, and treatment of" exact="chronic hepatitis" post="B: AASLD 2018 hepatitis B guidance. Hepatology2018; 67: 1560–1599.29405329"/>
  <result pre="10TerraultNALokASFMcMahonBJ, et al.Update on prevention, diagnosis, and treatment of chronic" exact="hepatitis" post="B: AASLD 2018 hepatitis B guidance. Hepatology2018; 67: 1560–1599.29405329"/>
  <result pre="prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018" exact="hepatitis" post="B guidance. Hepatology2018; 67: 1560–1599.29405329 11LamperticoPAgarwalKBergT, et al.EASL 2017"/>
  <result pre="et al.EASL 2017 Clinical Practice Guidelines on the management of" exact="hepatitis" post="B virus infection. J Hepatol2017; 67: 370–398.28427875 12LoombaRLiangTJHepatitis B"/>
  <result pre="2017 Clinical Practice Guidelines on the management of hepatitis B" exact="virus infection." post="J Hepatol2017; 67: 370–398.28427875 12LoombaRLiangTJHepatitis B reactivation associated with"/>
  <result pre="and future directions. Gastroenterology2017; 152: 1297–1309.28219691 13YeoWChanPKZhongS, et al.Frequency of" exact="hepatitis" post="B virus reactivation in cancer patients undergoing cytotoxic chemotherapy:"/>
  <result pre="1297–1309.28219691 13YeoWChanPKZhongS, et al.Frequency of hepatitis B virus reactivation in" exact="cancer" post="patients undergoing cytotoxic chemotherapy: a prospective study of 626"/>
  <result pre="Virol2000; 62: 299–307.11055239 14TohmeRABulkowLHomanCE, et al.Rates and risk factors for" exact="hepatitis" post="B reactivation in a cohort of persons in the"/>
  <result pre="in a cohort of persons in the inactive phase of" exact="chronic hepatitis" post="B-Alaska, 2001-2010. J Clin Virol2013; 58: 396–400.24001884 15HwangJPLokAS-FManagement of"/>
  <result pre="a cohort of persons in the inactive phase of chronic" exact="hepatitis" post="B-Alaska, 2001-2010. J Clin Virol2013; 58: 396–400.24001884 15HwangJPLokAS-FManagement of"/>
  <result pre="2001-2010. J Clin Virol2013; 58: 396–400.24001884 15HwangJPLokAS-FManagement of patients with" exact="hepatitis" post="B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol2014;"/>
  <result pre="Rev Gastroenterol Hepatol2014; 11: 209–219.24247262 16MoghoofeiMMostafaeiSAshraf-GanjoueiA, et al.HBV reactivation in" exact="rheumatic" post="diseases patients under therapy: a meta-analysis. Microb Pathog2018; 114:"/>
  <result pre="Gastroenterological Association Institute technical review on prevention and treatment of" exact="hepatitis" post="b virus reactivation during immunosuppressive drug therapy. Gastroenterology2015; 148:"/>
  <result pre="therapy. Gastroenterology2015; 148: 221–244e3. 18GalbraithRMEddlestonALWilliamsR, et al.Fulminant hepatic failure in" exact="leukaemia" post="and choriocarcinoma related to withdrawal of cytotoxic drug therapy."/>
  <result pre="148: 221–244e3. 18GalbraithRMEddlestonALWilliamsR, et al.Fulminant hepatic failure in leukaemia and" exact="choriocarcinoma" post="related to withdrawal of cytotoxic drug therapy. Lancet1975; 2:"/>
  <result pre="et al.The glucocorticoid receptor recognizes a specific nucleotide sequence in" exact="hepatitis" post="B virus DNA causing increased activity of the HBV"/>
  <result pre="alfa-2b alone and after prednisone withdrawal for the treatment of" exact="chronic hepatitis" post="B. The Hepatitis Interventional Therapy Group. N Engl J"/>
  <result pre="alone and after prednisone withdrawal for the treatment of chronic" exact="hepatitis" post="B. The Hepatitis Interventional Therapy Group. N Engl J"/>
  <result pre="prednisone withdrawal for the treatment of chronic hepatitis B. The" exact="Hepatitis" post="Interventional Therapy Group. N Engl J Med1990; 323: 295–301.2195346"/>
  <result pre="response and efficacy of subsequent lamivudine therapy in patients with" exact="chronic hepatitis" post="B. Hepatology2000; 32: 604–609.10960456 22HoofnagleJHDavisGLPappasSC, et al.A short course"/>
  <result pre="and efficacy of subsequent lamivudine therapy in patients with chronic" exact="hepatitis" post="B. Hepatology2000; 32: 604–609.10960456 22HoofnagleJHDavisGLPappasSC, et al.A short course"/>
  <result pre="with chronic hepatitis B. Hepatology2000; 32: 604–609.10960456 22HoofnagleJHDavisGLPappasSC, et al.A" exact="short" post="course of prednisolone in chronic type B hepatitis. Report"/>
  <result pre="32: 604–609.10960456 22HoofnagleJHDavisGLPappasSC, et al.A short course of prednisolone in" exact="chronic" post="type B hepatitis. Report of a randomized, double-blind, placebo-controlled"/>
  <result pre="604–609.10960456 22HoofnagleJHDavisGLPappasSC, et al.A short course of prednisolone in chronic" exact="type B" post="hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Ann"/>
  <result pre="Med1986; 104: 12–17.3940480 23ChengA-LHsiungCASuI-J, et al.Steroid-free chemotherapy decreases risk of" exact="hepatitis" post="B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology2003;"/>
  <result pre="HBV-carriers with lymphoma. Hepatology2003; 37: 1320–1328.12774010 24KimT-WKimM-NKwonJ-W, et al.Risk of" exact="hepatitis" post="B virus reactivation in patients with asthma or chronic"/>
  <result pre="et al.Risk of hepatitis B virus reactivation in patients with" exact="asthma" post="or chronic obstructive pulmonary disease treated with corticosteroids. Respirology2010;"/>
  <result pre="al.Risk of hepatitis B virus reactivation in patients with asthma" exact="or chronic" post="obstructive pulmonary disease treated with corticosteroids. Respirology2010; 15: 1092–1097.20630033"/>
  <result pre="of hepatitis B virus reactivation in patients with asthma or" exact="chronic" post="obstructive pulmonary disease treated with corticosteroids. Respirology2010; 15: 1092–1097.20630033"/>
  <result pre="B virus reactivation in patients with asthma or chronic obstructive" exact="pulmonary disease" post="treated with corticosteroids. Respirology2010; 15: 1092–1097.20630033 25ChenMHChenMHLiuCY, et al.Hepatitis"/>
  <result pre="virus reactivation in patients with asthma or chronic obstructive pulmonary" exact="disease" post="treated with corticosteroids. Respirology2010; 15: 1092–1097.20630033 25ChenMHChenMHLiuCY, et al.Hepatitis"/>
  <result pre="Respirology2010; 15: 1092–1097.20630033 25ChenMHChenMHLiuCY, et al.Hepatitis B virus reactivation in" exact="rheumatoid arthritis" post="patients undergoing biologics treatment. J Infect Dis2017; 215: 566–573.28011918"/>
  <result pre="15: 1092–1097.20630033 25ChenMHChenMHLiuCY, et al.Hepatitis B virus reactivation in rheumatoid" exact="arthritis" post="patients undergoing biologics treatment. J Infect Dis2017; 215: 566–573.28011918"/>
  <result pre="of dose and duration of corticosteroid on the risk of" exact="hepatitis" post="flare in patients with chronic hepatitis B. Liver Int2019;"/>
  <result pre="corticosteroid on the risk of hepatitis flare in patients with" exact="chronic hepatitis" post="B. Liver Int2019; 39: 271–279.30179316 27Braun-MoscoviciYBraunMSaadiT, et al.Safety of"/>
  <result pre="on the risk of hepatitis flare in patients with chronic" exact="hepatitis" post="B. Liver Int2019; 39: 271–279.30179316 27Braun-MoscoviciYBraunMSaadiT, et al.Safety of"/>
  <result pre="al.Safety of corticosteroid treatment in rheumatologic patients with markers of" exact="hepatitis" post="B viral infection. J Clin Rheumatol2016; 22: 364–368.27660934 28LinY-CLeeS-WYehH-Z,"/>
  <result pre="corticosteroid treatment in rheumatologic patients with markers of hepatitis B" exact="viral infection." post="J Clin Rheumatol2016; 22: 364–368.27660934 28LinY-CLeeS-WYehH-Z, et al.The prevalence"/>
  <result pre="22: 364–368.27660934 28LinY-CLeeS-WYehH-Z, et al.The prevalence and risk factors of" exact="hepatitis" post="B flares in chronic hepatitis B patients receiving glucocorticoid"/>
  <result pre="al.The prevalence and risk factors of hepatitis B flares in" exact="chronic hepatitis" post="B patients receiving glucocorticoid pulse therapy. Int J Clin"/>
  <result pre="prevalence and risk factors of hepatitis B flares in chronic" exact="hepatitis" post="B patients receiving glucocorticoid pulse therapy. Int J Clin"/>
  <result pre="glucocorticoid pulse therapy. Int J Clin Pharm2018; 40: 169–174.29322472 29YangC-HWuT-SChiuC-TChronic" exact="hepatitis" post="B reactivation: a word of caution regarding the use"/>
  <result pre="B reactivation: a word of caution regarding the use of" exact="systemic" post="glucocorticosteroid therapy. Br J Dermatol2007; 157: 587–90.17596145 30XuanDYuYShaoL, et"/>
  <result pre="Dermatol2007; 157: 587–90.17596145 30XuanDYuYShaoL, et al.Hepatitis reactivation in patients with" exact="rheumatic" post="diseases after immunosuppressive therapy - A report of long-term"/>
  <result pre="literature review. Clin Rheumatol2014; 33: 577–586.24343455 31WongGL-HWongVW-SYuenBW-Y, et al.Risk of" exact="hepatitis" post="B surface antigen seroreversion after corticosteroid treatment in patients"/>
  <result pre="surface antigen seroreversion after corticosteroid treatment in patients with previous" exact="hepatitis" post="B virus exposure. J Hepatol. Epub ahead of print"/>
  <result pre="al.Hepatitis B virus reactivation with corticosteroid therapy in patients with" exact="adrenal insufficiency." post="Endocrinol Diabetes Metab2019; e00071.31294085 33Di BisceglieAMLokASMartinP, et al.Recent US"/>
  <result pre="reactivation with corticosteroid therapy in patients with adrenal insufficiency. Endocrinol" exact="Diabetes" post="Metab2019; e00071.31294085 33Di BisceglieAMLokASMartinP, et al.Recent US Food and"/>
  <result pre="BisceglieAMLokASMartinP, et al.Recent US Food and Drug Administration warnings on" exact="hepatitis" post="B reactivation with immune-suppressing and anticancer drugs: just the"/>
  <result pre="61: 703–711.25412906 34LaohapandCArromdeeETanwandeeTLong-term use of methotrexate does not result in" exact="hepatitis" post="B reactivation in rheumatologic patients. Hepatol Int2015; 9: 202–208.25788188"/>
  <result pre="9: 202–208.25788188 35TangK-THungW-TChenY-H, et al.Methotrexate is not associated with increased" exact="liver cirrhosis" post="in a population-based cohort of rheumatoid arthritis patients with"/>
  <result pre="202–208.25788188 35TangK-THungW-TChenY-H, et al.Methotrexate is not associated with increased liver" exact="cirrhosis" post="in a population-based cohort of rheumatoid arthritis patients with"/>
  <result pre="associated with increased liver cirrhosis in a population-based cohort of" exact="rheumatoid arthritis" post="patients with chronic hepatitis B. Sci Rep2016; 6: 22387.26928373"/>
  <result pre="with increased liver cirrhosis in a population-based cohort of rheumatoid" exact="arthritis" post="patients with chronic hepatitis B. Sci Rep2016; 6: 22387.26928373"/>
  <result pre="cirrhosis in a population-based cohort of rheumatoid arthritis patients with" exact="chronic hepatitis" post="B. Sci Rep2016; 6: 22387.26928373 36TanJZhouJZhaoP, et al.Prospective study"/>
  <result pre="in a population-based cohort of rheumatoid arthritis patients with chronic" exact="hepatitis" post="B. Sci Rep2016; 6: 22387.26928373 36TanJZhouJZhaoP, et al.Prospective study"/>
  <result pre="22387.26928373 36TanJZhouJZhaoP, et al.Prospective study of HBV reactivation risk in" exact="rheumatoid arthritis" post="patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol2012;"/>
  <result pre="36TanJZhouJZhaoP, et al.Prospective study of HBV reactivation risk in rheumatoid" exact="arthritis" post="patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol2012;"/>
  <result pre="antirheumatic drugs. Clin Rheumatol2012; 31: 1169–1175.22544263 37FukudaWHanyuTKatayamaM, et al.Incidence of" exact="hepatitis" post="B virus reactivation in patients with resolved infection on"/>
  <result pre="al.Incidence of hepatitis B virus reactivation in patients with resolved" exact="infection" post="on immunosuppressive therapy for rheumatic disease: a multicentre, prospective,"/>
  <result pre="reactivation in patients with resolved infection on immunosuppressive therapy for" exact="rheumatic" post="disease: a multicentre, prospective, observational study in Japan. Ann"/>
  <result pre="acid, an immunosuppressive agent, inhibits HBV replication in vitro. J" exact="Viral" post="Hepat1999; 6: 229–236.10607235 39YingCDe ClercqENeytsJRibavirin and mycophenolic acid potentiate"/>
  <result pre="potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against" exact="hepatitis" post="B virus. Antiviral Res2000; 48: 117–124.11114413 40MaesBDvan PeltJFPeetersJC, et"/>
  <result pre="117–124.11114413 40MaesBDvan PeltJFPeetersJC, et al.The effect of mycophenolate mofetil on" exact="hepatitis" post="B viral load in stable renal transplant recipients with"/>
  <result pre="PeltJFPeetersJC, et al.The effect of mycophenolate mofetil on hepatitis B" exact="viral" post="load in stable renal transplant recipients with chronic hepatitis"/>
  <result pre="effect of mycophenolate mofetil on hepatitis B viral load in" exact="stable" post="renal transplant recipients with chronic hepatitis B. Transplantation2001; 72:"/>
  <result pre="hepatitis B viral load in stable renal transplant recipients with" exact="chronic hepatitis" post="B. Transplantation2001; 72: 1165–1166.11579320 41Ben-AriZZemelRTur-KaspaRThe addition of mycophenolate mofetil"/>
  <result pre="B viral load in stable renal transplant recipients with chronic" exact="hepatitis" post="B. Transplantation2001; 72: 1165–1166.11579320 41Ben-AriZZemelRTur-KaspaRThe addition of mycophenolate mofetil"/>
  <result pre="Transplantation2001; 72: 1165–1166.11579320 41Ben-AriZZemelRTur-KaspaRThe addition of mycophenolate mofetil for suppressing" exact="hepatitis" post="B virus replication in liver recipients who developed lamivudine"/>
  <result pre="a standard-dose prednisone regimen and mycophenolate mofetil combined with a" exact="lower" post="prednisone dose in chinese adults with idiopathic nephrotic syndrome"/>
  <result pre="with a lower prednisone dose in chinese adults with idiopathic" exact="nephrotic syndrome" post="who were carriers of hepatitis B surface antigen: a"/>
  <result pre="a lower prednisone dose in chinese adults with idiopathic nephrotic" exact="syndrome" post="who were carriers of hepatitis B surface antigen: a"/>
  <result pre="chinese adults with idiopathic nephrotic syndrome who were carriers of" exact="hepatitis" post="B surface antigen: a prospective cohort study. Clin Ther2009;"/>
  <result pre="study. Clin Ther2009; 31: 741–750.19446147 43LinWTChenYMChenDY, et al.Increased risk of" exact="hepatitis" post="B virus reactivation in systemic lupus erythematosus patients receiving"/>
  <result pre="43LinWTChenYMChenDY, et al.Increased risk of hepatitis B virus reactivation in" exact="systemic" post="lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study."/>
  <result pre="et al.Increased risk of hepatitis B virus reactivation in systemic" exact="lupus erythematosus" post="patients receiving immunosuppressants: a retrospective cohort study. Lupus2018; 27:"/>
  <result pre="Lupus2018; 27: 66–75.28534427 44SchwaneckECKroneMKreissl-KemmerS, et al.Management of anti-HBc-positive patients with" exact="rheumatic" post="diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of"/>
  <result pre="Rheumatol2018; 37: 2963–2970.30238380 45DrozNGilardinLCacoubP, et al.Kinetic profiles and management of" exact="hepatitis" post="B virus reactivation in patients with immune-mediated inflammatory diseases."/>
  <result pre="and management of hepatitis B virus reactivation in patients with" exact="immune-mediated inflammatory diseases." post="Arthritis Care Res2013; 65: 1504–1514. 46CarrollMBForgioneMAUse of tumor necrosis"/>
  <result pre="hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases." exact="Arthritis" post="Care Res2013; 65: 1504–1514. 46CarrollMBForgioneMAUse of tumor necrosis factor"/>
  <result pre="immune-mediated inflammatory diseases. Arthritis Care Res2013; 65: 1504–1514. 46CarrollMBForgioneMAUse of" exact="tumor" post="necrosis factor alpha inhibitors in hepatitis B surface antigen-positive"/>
  <result pre="65: 1504–1514. 46CarrollMBForgioneMAUse of tumor necrosis factor alpha inhibitors in" exact="hepatitis" post="B surface antigen-positive patients: a literature review and potential"/>
  <result pre="47VassilopoulosDApostolopoulouAHadziyannisE, et al.Long-term safety of anti-TNF treatment in patients with" exact="rheumatic" post="diseases and chronic or resolved hepatitis B virus infection."/>
  <result pre="safety of anti-TNF treatment in patients with rheumatic diseases and" exact="chronic" post="or resolved hepatitis B virus infection. Ann Rheum Dis2010;"/>
  <result pre="treatment in patients with rheumatic diseases and chronic or resolved" exact="hepatitis" post="B virus infection. Ann Rheum Dis2010; 69: 1352–1355.20472596 48Pérez-AlvarezRDíaz-LagaresCGarcía-HernándezF,"/>
  <result pre="patients with rheumatic diseases and chronic or resolved hepatitis B" exact="virus infection." post="Ann Rheum Dis2010; 69: 1352–1355.20472596 48Pérez-AlvarezRDíaz-LagaresCGarcía-HernándezF, et al.Hepatitis B"/>
  <result pre="48Pérez-AlvarezRDíaz-LagaresCGarcía-HernándezF, et al.Hepatitis B Virus (HBV) Reactivation in Patients Receiving" exact="Tumor" post="Necrosis Factor (TNF)-Targeted Therapy. Medicine2011; 90: 359–371.22033451 49LanJ-LChenY-MHsiehT-Y, et"/>
  <result pre="Factor (TNF)-Targeted Therapy. Medicine2011; 90: 359–371.22033451 49LanJ-LChenY-MHsiehT-Y, et al.Kinetics of" exact="viral" post="loads and risk of hepatitis B virus reactivation in"/>
  <result pre="359–371.22033451 49LanJ-LChenY-MHsiehT-Y, et al.Kinetics of viral loads and risk of" exact="hepatitis" post="B virus reactivation in hepatitis B core antibody-positive rheumatoid"/>
  <result pre="viral loads and risk of hepatitis B virus reactivation in" exact="hepatitis" post="B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis"/>
  <result pre="of hepatitis B virus reactivation in hepatitis B core antibody-positive" exact="rheumatoid arthritis" post="patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum"/>
  <result pre="hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid" exact="arthritis" post="patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum"/>
  <result pre="therapy. Ann Rheum Dis2011; 70: 1719–1725.21719446 50ZingarelliSFrassiMBazzaniC, et al.Use of" exact="tumor" post="necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports"/>
  <result pre="1719–1725.21719446 50ZingarelliSFrassiMBazzaniC, et al.Use of tumor necrosis factor-alpha-blocking agents in" exact="hepatitis" post="B virus-positive patients: reports of 3 cases and review"/>
  <result pre="the literature. J Rheumatol2009; 36: 1188–1194.19447932 51ChungSKimJKParkM-C, et al.Reactivation of" exact="hepatitis" post="B viral infection in inactive HBsAg carriers following anti-tumor"/>
  <result pre="J Rheumatol2009; 36: 1188–1194.19447932 51ChungSKimJKParkM-C, et al.Reactivation of hepatitis B" exact="viral infection" post="in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy."/>
  <result pre="Rheumatol2009; 36: 1188–1194.19447932 51ChungSKimJKParkM-C, et al.Reactivation of hepatitis B viral" exact="infection" post="in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy."/>
  <result pre="Rheumatol2009; 36: 2416–2420.19797507 52TamoriAKoikeTGotoH, et al.Prospective study of reactivation of" exact="hepatitis" post="B virus in patients with rheumatoid arthritis who received"/>
  <result pre="study of reactivation of hepatitis B virus in patients with" exact="rheumatoid arthritis" post="who received immunosuppressive therapy: evaluation of both HBsAg-positive and"/>
  <result pre="of reactivation of hepatitis B virus in patients with rheumatoid" exact="arthritis" post="who received immunosuppressive therapy: evaluation of both HBsAg-positive and"/>
  <result pre="Gastroenterol2011; 46: 556–564.21246383 53RyuHHLeeEYBShinK, et al.Hepatitis B virus reactivation in" exact="rheumatoid arthritis" post="and ankylosing spondylitis patients treated with anti-TNFα agents: a"/>
  <result pre="46: 556–564.21246383 53RyuHHLeeEYBShinK, et al.Hepatitis B virus reactivation in rheumatoid" exact="arthritis" post="and ankylosing spondylitis patients treated with anti-TNFα agents: a"/>
  <result pre="53RyuHHLeeEYBShinK, et al.Hepatitis B virus reactivation in rheumatoid arthritis and" exact="ankylosing spondylitis" post="patients treated with anti-TNFα agents: a retrospective analysis of"/>
  <result pre="et al.Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing" exact="spondylitis" post="patients treated with anti-TNFα agents: a retrospective analysis of"/>
  <result pre="therapy in patients with HBV infection-analysis of 87 patients with" exact="inflammatory arthritis." post="Clin Rheumatol2014; 33: 119–123.24077913 55MoriS, et al.Past hepatitis B"/>
  <result pre="with inflammatory arthritis. Clin Rheumatol2014; 33: 119–123.24077913 55MoriS, et al.Past" exact="hepatitis" post="B virus infection in rheumatoid arthritis patients receiving biological"/>
  <result pre="arthritis. Clin Rheumatol2014; 33: 119–123.24077913 55MoriS, et al.Past hepatitis B" exact="virus infection" post="in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying"/>
  <result pre="Clin Rheumatol2014; 33: 119–123.24077913 55MoriS, et al.Past hepatitis B virus" exact="infection" post="in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying"/>
  <result pre="33: 119–123.24077913 55MoriS, et al.Past hepatitis B virus infection in" exact="rheumatoid arthritis" post="patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod"/>
  <result pre="119–123.24077913 55MoriS, et al.Past hepatitis B virus infection in rheumatoid" exact="arthritis" post="patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod"/>
  <result pre="antirheumatic drugs. Mod Rheumatol2011; 21: 621–627.21528424 56CaporaliRBobbio-PallaviciniFAtzeniF, et al.Safety of" exact="tumor" post="necrosis factor alpha blockers in hepatitis B virus occult"/>
  <result pre="56CaporaliRBobbio-PallaviciniFAtzeniF, et al.Safety of tumor necrosis factor alpha blockers in" exact="hepatitis" post="B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis"/>
  <result pre="(hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with" exact="rheumatic" post="diseases. Arthritis Care Res2010; 62: 749–754. 57LeeYHBaeSCSongGGHepatitis B virus"/>
  <result pre="surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases." exact="Arthritis" post="Care Res2010; 62: 749–754. 57LeeYHBaeSCSongGGHepatitis B virus (HBV) reactivation"/>
  <result pre="Care Res2010; 62: 749–754. 57LeeYHBaeSCSongGGHepatitis B virus (HBV) reactivation in" exact="rheumatic" post="patients with hepatitis core antigen (HBV occult carriers) undergoing"/>
  <result pre="749–754. 57LeeYHBaeSCSongGGHepatitis B virus (HBV) reactivation in rheumatic patients with" exact="hepatitis" post="core antigen (HBV occult carriers) undergoing anti-tumour necrosis factor"/>
  <result pre="long-term biologic therapy in rheumatologic patients with a previously resolved" exact="hepatitis" post="B viral infection. Hepatology2015; 62: 40–46.25613809 59Evens a.MJovanovicBDSuYC, et"/>
  <result pre="therapy in rheumatologic patients with a previously resolved hepatitis B" exact="viral infection." post="Hepatology2015; 62: 40–46.25613809 59Evens a.MJovanovicBDSuYC, et al.Rituximab-associated hepatitis B"/>
  <result pre="B viral infection. Hepatology2015; 62: 40–46.25613809 59Evens a.MJovanovicBDSuYC, et al.Rituximab-associated" exact="hepatitis" post="B virus (HBV) reactivation in lymphoproliferative diseases: Metaanalysis and"/>
  <result pre="examination of FDA safety reports. Ann Oncol2011; 22: 1170–1180.21115603 60MitkaMFDA:" exact="Increased" post="HBV reactivation risk with ofatumumab or rituximab. JAMA2013; 310:"/>
  <result pre="ofatumumab or rituximab. JAMA2013; 310: 1664.24150447 61PeiS-NChenC-HLeeC-M, et al.Reactivation of" exact="hepatitis" post="B virus following rituximab-based regimens: a serious complication in"/>
  <result pre="62PaulSSaxenaATerrinN, et al.Hepatitis B virus reactivation and prophylaxis during solid" exact="tumor" post="chemotherapy: a systematic review and meta-analysis. Ann Intern Med2016;"/>
  <result pre="30–40.26595058 63HsuCHsiungCASuIJ, et al.A revisit of prophylactic lamivudine for chemotherapy-associated" exact="hepatitis" post="B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology2008;"/>
  <result pre="et al.Early is superior to deferred preemptive lamivudine therapy for" exact="hepatitis" post="B patients undergoing chemotherapy. Gastroenterology2003; 125: 1742–1749.14724827 65HuangHLiXZhuJ, et"/>
  <result pre="125: 1742–1749.14724827 65HuangHLiXZhuJ, et al.Entecavir vs lamivudine for prevention of" exact="hepatitis" post="B virus reactivation among patients with untreated diffuse large"/>
  <result pre="prevention of hepatitis B virus reactivation among patients with untreated" exact="diffuse large B-cell lymphoma" post="receiving R-CHOP chemotherapy. JAMA2014; 312: 2521.25514302 66PyrpasopoulouADoumaSVassiliadisT, et al.Reactivation"/>
  <result pre="hepatitis B virus reactivation among patients with untreated diffuse large" exact="B-cell lymphoma" post="receiving R-CHOP chemotherapy. JAMA2014; 312: 2521.25514302 66PyrpasopoulouADoumaSVassiliadisT, et al.Reactivation"/>
  <result pre="B virus reactivation among patients with untreated diffuse large B-cell" exact="lymphoma" post="receiving R-CHOP chemotherapy. JAMA2014; 312: 2521.25514302 66PyrpasopoulouADoumaSVassiliadisT, et al.Reactivation"/>
  <result pre="receiving R-CHOP chemotherapy. JAMA2014; 312: 2521.25514302 66PyrpasopoulouADoumaSVassiliadisT, et al.Reactivation of" exact="chronic hepatitis" post="B virus infection following rituximab administration for rheumatoid arthritis."/>
  <result pre="R-CHOP chemotherapy. JAMA2014; 312: 2521.25514302 66PyrpasopoulouADoumaSVassiliadisT, et al.Reactivation of chronic" exact="hepatitis" post="B virus infection following rituximab administration for rheumatoid arthritis."/>
  <result pre="JAMA2014; 312: 2521.25514302 66PyrpasopoulouADoumaSVassiliadisT, et al.Reactivation of chronic hepatitis B" exact="virus infection" post="following rituximab administration for rheumatoid arthritis. Rheumatol Int2011; 31:"/>
  <result pre="312: 2521.25514302 66PyrpasopoulouADoumaSVassiliadisT, et al.Reactivation of chronic hepatitis B virus" exact="infection" post="following rituximab administration for rheumatoid arthritis. Rheumatol Int2011; 31:"/>
  <result pre="of chronic hepatitis B virus infection following rituximab administration for" exact="rheumatoid arthritis." post="Rheumatol Int2011; 31: 403–404.19830433 67HuiC-KCheungWWWZhangH-Y, et al.Kinetics and risk"/>
  <result pre="31: 403–404.19830433 67HuiC-KCheungWWWZhangH-Y, et al.Kinetics and risk of de novo" exact="hepatitis" post="B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology2006;"/>
  <result pre="67HuiC-KCheungWWWZhangH-Y, et al.Kinetics and risk of de novo hepatitis B" exact="infection" post="in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology2006; 131: 59–68.16831590"/>
  <result pre="59–68.16831590 68SetoW-KChanTSYHwangY-Y, et al.Hepatitis B reactivation in patients with previous" exact="hepatitis" post="B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a"/>
  <result pre="prospective study. J Clin Oncol2014; 32: 3736–3743.25287829 69HsuCTsouH-HLinS-F, et al.Chemotherapy-induced" exact="hepatitis" post="B reactivation in lymphoma patients with resolved HBV infection:"/>
  <result pre="Oncol2014; 32: 3736–3743.25287829 69HsuCTsouH-HLinS-F, et al.Chemotherapy-induced hepatitis B reactivation in" exact="lymphoma" post="patients with resolved HBV infection: a prospective study. Hepatology2014;"/>
  <result pre="a prospective study. Hepatology2014; 59: 2092–2100.24002804 70KooYXTayMTehYE, et al.Risk of" exact="hepatitis" post="B virus (HBV) reactivation in hepatitis B surface antigen"/>
  <result pre="70KooYXTayMTehYE, et al.Risk of hepatitis B virus (HBV) reactivation in" exact="hepatitis" post="B surface antigen negative/hepatitis B core antibody positive patients"/>
  <result pre="71HuangY-HHsiaoL-THongY-C, et al.Randomized controlled trial of entecavir prophylaxis for rituximab-associated" exact="hepatitis" post="B virus reactivation in patients with lymphoma and resolved"/>
  <result pre="prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with" exact="lymphoma" post="and resolved hepatitis B. J Clin Oncol2013; 31: 2765–2772.23775967"/>
  <result pre="hepatitis B virus reactivation in patients with lymphoma and resolved" exact="hepatitis" post="B. J Clin Oncol2013; 31: 2765–2772.23775967 72MitroulisIHatzaraCKandiliA, et al.Long-term"/>
  <result pre="2765–2772.23775967 72MitroulisIHatzaraCKandiliA, et al.Long-term safety of rituximab in patients with" exact="rheumatic" post="diseases and chronic or resolved hepatitis B virus infection."/>
  <result pre="al.Long-term safety of rituximab in patients with rheumatic diseases and" exact="chronic" post="or resolved hepatitis B virus infection. Ann Rheum Dis2013;"/>
  <result pre="rituximab in patients with rheumatic diseases and chronic or resolved" exact="hepatitis" post="B virus infection. Ann Rheum Dis2013; 72: 308–310.22930597 73van"/>
  <result pre="patients with rheumatic diseases and chronic or resolved hepatitis B" exact="virus infection." post="Ann Rheum Dis2013; 72: 308–310.22930597 73van VollenhovenRFFleischmannRMFurstDE, et al.Longterm"/>
  <result pre="VollenhovenRFFleischmannRMFurstDE, et al.Longterm safety of rituximab: final report of the" exact="rheumatoid arthritis" post="global clinical trial program over 11 years. J Rheumatol2015;"/>
  <result pre="et al.Longterm safety of rituximab: final report of the rheumatoid" exact="arthritis" post="global clinical trial program over 11 years. J Rheumatol2015;"/>
  <result pre="years. J Rheumatol2015; 42: 1761–1766.26276965 74VariscoVViganòMBatticciottoA, et al.Low risk of" exact="hepatitis" post="B virus reactivation in HBsAg-negative/anti-HBc-positive carriers receiving rituximab for"/>
  <result pre="75PapalopoulosIFanouriakisAKougkasN, et al.Liver safety of non-tumour necrosis factor inhibitors in" exact="rheumatic" post="patients with past hepatitis B virus infection: an observational,"/>
  <result pre="of non-tumour necrosis factor inhibitors in rheumatic patients with past" exact="hepatitis" post="B virus infection: an observational, controlled, long-term study. Clin"/>
  <result pre="Clin Exp Rheumatol2018; 36: 102–109. 76TienY-CYenH-HChiuY-MIncidence and clinical characteristics of" exact="hepatitis" post="B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for"/>
  <result pre="hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for" exact="rheumatoid arthritis." post="Clin Exp Rheumatol35: 831–836.28375829 77KimPSHoGYPretePE, et al.Safety and efficacy"/>
  <result pre="831–836.28375829 77KimPSHoGYPretePE, et al.Safety and efficacy of abatacept in eight" exact="rheumatoid arthritis" post="patients with chronic hepatitis B. Arthritis Care Res2012; 64:"/>
  <result pre="77KimPSHoGYPretePE, et al.Safety and efficacy of abatacept in eight rheumatoid" exact="arthritis" post="patients with chronic hepatitis B. Arthritis Care Res2012; 64:"/>
  <result pre="and efficacy of abatacept in eight rheumatoid arthritis patients with" exact="chronic hepatitis" post="B. Arthritis Care Res2012; 64: 1265–1268. 78PadovanMFilippiniMTincaniA, et al.Safety"/>
  <result pre="efficacy of abatacept in eight rheumatoid arthritis patients with chronic" exact="hepatitis" post="B. Arthritis Care Res2012; 64: 1265–1268. 78PadovanMFilippiniMTincaniA, et al.Safety"/>
  <result pre="abatacept in eight rheumatoid arthritis patients with chronic hepatitis B." exact="Arthritis" post="Care Res2012; 64: 1265–1268. 78PadovanMFilippiniMTincaniA, et al.Safety of abatacept"/>
  <result pre="Care Res2012; 64: 1265–1268. 78PadovanMFilippiniMTincaniA, et al.Safety of abatacept in" exact="rheumatoid arthritis" post="with serologic evidence of past or present hepatitis B"/>
  <result pre="Res2012; 64: 1265–1268. 78PadovanMFilippiniMTincaniA, et al.Safety of abatacept in rheumatoid" exact="arthritis" post="with serologic evidence of past or present hepatitis B"/>
  <result pre="in rheumatoid arthritis with serologic evidence of past or present" exact="hepatitis" post="B virus infection. Arthritis Care Res2016; 68: 738–743. 79FanouriakisAVassilopoulosDRepaA,"/>
  <result pre="arthritis with serologic evidence of past or present hepatitis B" exact="virus infection." post="Arthritis Care Res2016; 68: 738–743. 79FanouriakisAVassilopoulosDRepaA, et al.Hepatitis B"/>
  <result pre="serologic evidence of past or present hepatitis B virus infection." exact="Arthritis" post="Care Res2016; 68: 738–743. 79FanouriakisAVassilopoulosDRepaA, et al.Hepatitis B reactivation"/>
  <result pre="reactivation following treatment with abatacept in a patient with past" exact="hepatitis" post="B virus infection. Rheumatology2014; 53: 195–196.23771951 80GermanidisGHytiroglouPZakalkaM, et al.Reactivation"/>
  <result pre="treatment with abatacept in a patient with past hepatitis B" exact="virus infection." post="Rheumatology2014; 53: 195–196.23771951 80GermanidisGHytiroglouPZakalkaM, et al.Reactivation of occult hepatitis"/>
  <result pre="virus infection. Rheumatology2014; 53: 195–196.23771951 80GermanidisGHytiroglouPZakalkaM, et al.Reactivation of occult" exact="hepatitis" post="B virus infection, following treatment of refractory rheumatoid arthritis"/>
  <result pre="Rheumatology2014; 53: 195–196.23771951 80GermanidisGHytiroglouPZakalkaM, et al.Reactivation of occult hepatitis B" exact="virus infection," post="following treatment of refractory rheumatoid arthritis with abatacept. J"/>
  <result pre="of occult hepatitis B virus infection, following treatment of refractory" exact="rheumatoid arthritis" post="with abatacept. J Hepatol2012; 56: 1420–1421.22127282 81WatanabeTFukaeJFukayaS, et al.Incidence"/>
  <result pre="occult hepatitis B virus infection, following treatment of refractory rheumatoid" exact="arthritis" post="with abatacept. J Hepatol2012; 56: 1420–1421.22127282 81WatanabeTFukaeJFukayaS, et al.Incidence"/>
  <result pre="81WatanabeTFukaeJFukayaS, et al.Incidence and risk factors for reactivation from resolved" exact="hepatitis" post="B virus in rheumatoid arthritis patients treated with biological"/>
  <result pre="risk factors for reactivation from resolved hepatitis B virus in" exact="rheumatoid arthritis" post="patients treated with biological disease-modifying antirheumatic drugs. Int J"/>
  <result pre="factors for reactivation from resolved hepatitis B virus in rheumatoid" exact="arthritis" post="patients treated with biological disease-modifying antirheumatic drugs. Int J"/>
  <result pre="Rheum Dis2019; 22: 574–582.30338649 82WinthropKLMarietteXSilvaJT, et al.ESCMID Study Group for" exact="Infections" post="in Compromised Hosts (ESGICH) Consensus Document on the safety"/>
  <result pre="Document on the safety of targeted and biological therapies: an" exact="infectious diseases" post="perspective (Soluble immune effector molecules [II]: agents targeting interleukins,"/>
  <result pre="Infect2018; 24: S21–S40.29447987 83NagashimaTMinotaSLong-term tocilizumab therapy in a patient with" exact="rheumatoid arthritis" post="and chronic hepatitis B. Rheumatology2008; 47: 1838–1840. 84TsuboiHTsujiiANampeiA, et"/>
  <result pre="24: S21–S40.29447987 83NagashimaTMinotaSLong-term tocilizumab therapy in a patient with rheumatoid" exact="arthritis" post="and chronic hepatitis B. Rheumatology2008; 47: 1838–1840. 84TsuboiHTsujiiANampeiA, et"/>
  <result pre="83NagashimaTMinotaSLong-term tocilizumab therapy in a patient with rheumatoid arthritis and" exact="chronic hepatitis" post="B. Rheumatology2008; 47: 1838–1840. 84TsuboiHTsujiiANampeiA, et al.A patient with"/>
  <result pre="tocilizumab therapy in a patient with rheumatoid arthritis and chronic" exact="hepatitis" post="B. Rheumatology2008; 47: 1838–1840. 84TsuboiHTsujiiANampeiA, et al.A patient with"/>
  <result pre="hepatitis B. Rheumatology2008; 47: 1838–1840. 84TsuboiHTsujiiANampeiA, et al.A patient with" exact="rheumatoid arthritis" post="treated with tocilizumab together with lamivudine prophylaxis after remission"/>
  <result pre="B. Rheumatology2008; 47: 1838–1840. 84TsuboiHTsujiiANampeiA, et al.A patient with rheumatoid" exact="arthritis" post="treated with tocilizumab together with lamivudine prophylaxis after remission"/>
  <result pre="with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated" exact="hepatitis" post="B. Mod Rheumatol2011; 21: 701–705.21626075 85KishidaDOkudaYOnishiM, et al.Successful tocilizumab"/>
  <result pre="et al.Successful tocilizumab treatment in a patient with adult-onset Still’s" exact="disease" post="complicated by chronic active hepatitis B and amyloid A"/>
  <result pre="treatment in a patient with adult-onset Still’s disease complicated by" exact="chronic" post="active hepatitis B and amyloid A amyloidosis. Mod Rheumatol2011;"/>
  <result pre="a patient with adult-onset Still’s disease complicated by chronic active" exact="hepatitis" post="B and amyloid A amyloidosis. Mod Rheumatol2011; 21: 215–218.20931272"/>
  <result pre="Rheumatol2011; 21: 215–218.20931272 86ChenL-FMoY-QJingJ, et al.Short-course tocilizumab increases risk of" exact="hepatitis" post="B virus reactivation in patients with rheumatoid arthritis: a"/>
  <result pre="Rheum Dis2017; 20: 859–869.28160426 87AhnSSJungSMSongJJ, et al.Safety of tocilizumab in" exact="rheumatoid arthritis" post="patients with resolved hepatitis B virus infection: data from"/>
  <result pre="Dis2017; 20: 859–869.28160426 87AhnSSJungSMSongJJ, et al.Safety of tocilizumab in rheumatoid" exact="arthritis" post="patients with resolved hepatitis B virus infection: data from"/>
  <result pre="et al.Safety of tocilizumab in rheumatoid arthritis patients with resolved" exact="hepatitis" post="B virus infection: data from real-world experience. Yonsei Med"/>
  <result pre="experience. Yonsei Med J2018; 59: 452–456.29611409 88NakamuraJNagashimaTNagataniK, et al.Reactivation of" exact="hepatitis" post="B virus in rheumatoid arthritis patients treated with biological"/>
  <result pre="59: 452–456.29611409 88NakamuraJNagashimaTNagataniK, et al.Reactivation of hepatitis B virus in" exact="rheumatoid arthritis" post="patients treated with biological disease-modifying antirheumatic drugs. Int J"/>
  <result pre="452–456.29611409 88NakamuraJNagashimaTNagataniK, et al.Reactivation of hepatitis B virus in rheumatoid" exact="arthritis" post="patients treated with biological disease-modifying antirheumatic drugs. Int J"/>
  <result pre="Int J Rheum Dis2014; 19(5): 470–475.24698305 89SnastIAtzmonyLBraunM, et al.Risk for" exact="hepatitis" post="B and C virus reactivation in patients with psoriasis"/>
  <result pre="for hepatitis B and C virus reactivation in patients with" exact="psoriasis" post="on biologic therapies: a retrospective cohort study and systematic"/>
  <result pre="Acad Dermatol2017; 77: 88–97.e5.28495497 90YanagiharaSSugitaKYoshidaY, et al.Psoriasis vulgaris in a" exact="hepatitis" post="B virus carrier successfully treated with secukinumab and entecavir"/>
  <result pre="entecavir combination therapy. Eur J Dermatol2017; 27: 185–186.27965188 91FeasterBClineAFeldmanSRSecukinumab for" exact="psoriasis" post="in a patient with hepatitis B. Dermatol Online J2018;"/>
  <result pre="Dermatol2017; 27: 185–186.27965188 91FeasterBClineAFeldmanSRSecukinumab for psoriasis in a patient with" exact="hepatitis" post="B. Dermatol Online J2018; 24: 4–6. 92PeccerilloFOdoriciGPellacaniG, et al.Secukinumab:"/>
  <result pre="et al.Secukinumab: a positive outcome in a patient with severe" exact="psoriasis" post="and HBV-HCV co-infection. Dermatol Ther2018; 31: 1–2. 93LoraVGraceffaDDe FeliceC,"/>
  <result pre="Dermatol Ther2018; 31: 1–2. 93LoraVGraceffaDDe FeliceC, et al.Treatment of severe" exact="psoriasis" post="with ixekizumab in a liver transplant recipient with concomitant"/>
  <result pre="psoriasis with ixekizumab in a liver transplant recipient with concomitant" exact="hepatitis" post="B virus infection. Dermatol Ther; 32 Epub ahead of"/>
  <result pre="ixekizumab in a liver transplant recipient with concomitant hepatitis B" exact="virus infection." post="Dermatol Ther; 32 Epub ahead of print 23 May"/>
  <result pre="10.1111/dth.12909. 94KoikeYFujikiYHiguchiM, et al.An interleukin-17 inhibitor successfully treated a complicated" exact="psoriasis" post="and psoriatic arthritis patient with hepatitis B virus infection"/>
  <result pre="et al.An interleukin-17 inhibitor successfully treated a complicated psoriasis and" exact="psoriatic arthritis" post="patient with hepatitis B virus infection and end-stage kidney"/>
  <result pre="al.An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic" exact="arthritis" post="patient with hepatitis B virus infection and end-stage kidney"/>
  <result pre="successfully treated a complicated psoriasis and psoriatic arthritis patient with" exact="hepatitis" post="B virus infection and end-stage kidney disease on hemodialysis."/>
  <result pre="a complicated psoriasis and psoriatic arthritis patient with hepatitis B" exact="virus infection" post="and end-stage kidney disease on hemodialysis. JAAD Case Reports2019;"/>
  <result pre="complicated psoriasis and psoriatic arthritis patient with hepatitis B virus" exact="infection" post="and end-stage kidney disease on hemodialysis. JAAD Case Reports2019;"/>
  <result pre="psoriatic arthritis patient with hepatitis B virus infection and end-stage" exact="kidney disease" post="on hemodialysis. JAAD Case Reports2019; 5: 150–152.30733983 95ChiuHHuiRHuangY, et"/>
  <result pre="arthritis patient with hepatitis B virus infection and end-stage kidney" exact="disease" post="on hemodialysis. JAAD Case Reports2019; 5: 150–152.30733983 95ChiuHHuiRHuangY, et"/>
  <result pre="et al.Safety Profile of secukinumab in treatment of patients with" exact="psoriasis" post="and concurrent hepatitis B or C: a multicentric prospective"/>
  <result pre="of secukinumab in treatment of patients with psoriasis and concurrent" exact="hepatitis" post="B or C: a multicentric prospective cohort study. Acta"/>
  <result pre="safety profile of ustekinumab in the treatment of patients with" exact="psoriasis" post="and concurrent hepatitis B or C. Br J Dermatol2013;"/>
  <result pre="ustekinumab in the treatment of patients with psoriasis and concurrent" exact="hepatitis" post="B or C. Br J Dermatol2013; 169: 1295–1303.23746170 97TingS-WChenY-CHuangY-HRisk"/>
  <result pre="B or C. Br J Dermatol2013; 169: 1295–1303.23746170 97TingS-WChenY-CHuangY-HRisk of" exact="hepatitis" post="B reactivation in patients with psoriasis on ustekinumab. Clin"/>
  <result pre="169: 1295–1303.23746170 97TingS-WChenY-CHuangY-HRisk of hepatitis B reactivation in patients with" exact="psoriasis" post="on ustekinumab. Clin Drug Investig2018; 38: 873–880. 98SchwartzDMKannoYVillarinoA, et"/>
  <result pre="Nat Rev Drug Discov2017; 17: 78. 99ChenY-MHuangW-NWuY-D, et al.Reactivation of" exact="hepatitis" post="B virus infection in patients with rheumatoid arthritis receiving"/>
  <result pre="Drug Discov2017; 17: 78. 99ChenY-MHuangW-NWuY-D, et al.Reactivation of hepatitis B" exact="virus infection" post="in patients with rheumatoid arthritis receiving tofacitinib: a real-world"/>
  <result pre="Discov2017; 17: 78. 99ChenY-MHuangW-NWuY-D, et al.Reactivation of hepatitis B virus" exact="infection" post="in patients with rheumatoid arthritis receiving tofacitinib: a real-world"/>
  <result pre="et al.Reactivation of hepatitis B virus infection in patients with" exact="rheumatoid arthritis" post="receiving tofacitinib: a real-world study. Ann Rheum Dis2018; 77:"/>
  <result pre="al.Reactivation of hepatitis B virus infection in patients with rheumatoid" exact="arthritis" post="receiving tofacitinib: a real-world study. Ann Rheum Dis2018; 77:"/>
  <result pre="real-world study. Ann Rheum Dis2018; 77: 780–782.28663308 100HarigaiMWinthropKTakeuchiT, et al.FRI0077" exact="Hepatitis" post="b virus reactivation in patients with rheumatoid arthritis treated"/>
  <result pre="100HarigaiMWinthropKTakeuchiT, et al.FRI0077 Hepatitis b virus reactivation in patients with" exact="rheumatoid arthritis" post="treated with baricitinib: post-hoc analysis from clinical trials. Ann"/>
  <result pre="et al.FRI0077 Hepatitis b virus reactivation in patients with rheumatoid" exact="arthritis" post="treated with baricitinib: post-hoc analysis from clinical trials. Ann"/>
  <result pre="et al.Seroprevalence of HBV (anti-HBc, HBsAg and anti-HBs) and HDV" exact="infections" post="among 9006 women at delivery. Liver1996; 16: 110–116.8740844 102De"/>
  <result pre="Liver1996; 16: 110–116.8740844 102De PaschaleMMancoMTBelvisiL, et al.Prevalence of markers of" exact="hepatitis" post="B virus infection or vaccination in HBsAg-negative subjects. Blood"/>
  <result pre="110–116.8740844 102De PaschaleMMancoMTBelvisiL, et al.Prevalence of markers of hepatitis B" exact="virus infection" post="or vaccination in HBsAg-negative subjects. Blood Transfus2012; 10: 344–350.22682333"/>
  <result pre="102De PaschaleMMancoMTBelvisiL, et al.Prevalence of markers of hepatitis B virus" exact="infection" post="or vaccination in HBsAg-negative subjects. Blood Transfus2012; 10: 344–350.22682333"/>
  <result pre="of hepatitis B virus infection or vaccination in HBsAg-negative subjects." exact="Blood" post="Transfus2012; 10: 344–350.22682333 103ChoYYuSJChoEJ, et al.High titers of anti-HBs"/>
  <result pre="10: 344–350.22682333 103ChoYYuSJChoEJ, et al.High titers of anti-HBs prevent rituximab-related" exact="viral" post="reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma."/>
  <result pre="al.High titers of anti-HBs prevent rituximab-related viral reactivation in resolved" exact="hepatitis" post="B patient with non-Hodgkin’s lymphoma. J Med Virol2016; 88:"/>
  <result pre="Virol2016; 88: 1010–1017.26531242 104KotakeTSatakeHOkitaY, et al.Prevalence and risk factors of" exact="hepatitis" post="B virus reactivation in patients with solid tumors with"/>
  <result pre="Oncol2019; 15: 63–68.29984542 105PaulSDicksteinASaxenaA, et al.Role of surface antibody in" exact="hepatitis" post="B reactivation in patients with resolved infection and hematologic"/>
  <result pre="surface antibody in hepatitis B reactivation in patients with resolved" exact="infection" post="and hematologic malignancy: a meta-analysis. Hepatology2017; 66: 379–388.28128861 106TienY-CHsueY-THungM-H,"/>
  <result pre="malignancy: a meta-analysis. Hepatology2017; 66: 379–388.28128861 106TienY-CHsueY-THungM-H, et al.Changes in" exact="hepatitis" post="B virus surface antibody titer and risk of hepatitis"/>
  <result pre="in hepatitis B virus surface antibody titer and risk of" exact="hepatitis" post="B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for"/>
  <result pre="hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for" exact="rheumatic" post="diseases: a prospective cohort study. Arthritis Res Ther2018; 20:"/>
  <result pre="undergoing biologic therapy for rheumatic diseases: a prospective cohort study." exact="Arthritis" post="Res Ther2018; 20: 246.30382902 107CholongitasEHaidichABApostolidou-KioutiF, et al.Hepatitis b virus"/>
  <result pre="Project. Hepatology2014; 106–113.24585503 109KonijetiGGGrandheSKonermanM, et al.Cost-effectiveness analysis of screening for" exact="hepatitis" post="B virus infection in patients with solid tumors before"/>
  <result pre="106–113.24585503 109KonijetiGGGrandheSKonermanM, et al.Cost-effectiveness analysis of screening for hepatitis B" exact="virus infection" post="in patients with solid tumors before initiating chemotherapy. Clin"/>
  <result pre="109KonijetiGGGrandheSKonermanM, et al.Cost-effectiveness analysis of screening for hepatitis B virus" exact="infection" post="in patients with solid tumors before initiating chemotherapy. Clin"/>
  <result pre="31 October 2019. DOI: 10.1016/j.cgh.2019.10.039. 110CrespoJEstebanRTorresC, et al.Cost-effectiveness of a" exact="hepatitis" post="B virus screening strategy to prevent reactivation in patients"/>
  <result pre="Esp Enferm Dig2017; 109: 619–626.28648087 111HwangJPHuangDVierlingJM, et al.Cost-effectiveness analysis of" exact="hepatitis" post="B virus screening and management in patients with hematologic"/>
  <result pre="management in patients with hematologic or solid malignancies anticipating immunosuppressive" exact="cancer" post="therapy. JCO Clin Cancer Informatics2019; 3: 1–12. 112MastEEWeinbaumCMFioreAE, et"/>
  <result pre="hematologic or solid malignancies anticipating immunosuppressive cancer therapy. JCO Clin" exact="Cancer" post="Informatics2019; 3: 1–12. 112MastEEWeinbaumCMFioreAE, et al.A comprehensive immunization strategy"/>
  <result pre="112MastEEWeinbaumCMFioreAE, et al.A comprehensive immunization strategy to eliminate transmission of" exact="hepatitis" post="B virus infection in the United States: recommendations of"/>
  <result pre="al.A comprehensive immunization strategy to eliminate transmission of hepatitis B" exact="virus infection" post="in the United States: recommendations of the Advisory Committee"/>
  <result pre="comprehensive immunization strategy to eliminate transmission of hepatitis B virus" exact="infection" post="in the United States: recommendations of the Advisory Committee"/>
  <result pre="reports2006; 55: 1–33; quiz CE1–4. 113ThomasKVassilopoulosDImmunization in patients with inflammatory" exact="rheumatic" post="diseases. Best Pract Res Clin Rheumatol2016; 30: 946–963.27964798 114KimDKHunterPWoodsLD,"/>
  <result pre="Best Pract Res Clin Rheumatol2016; 30: 946–963.27964798 114KimDKHunterPWoodsLD, et al.Recommended" exact="adult" post="immunization schedule, United States, 2019. Ann Intern Med2019; 170:"/>
  <result pre="the Advisory Committee on Immunization Practices for Use of a" exact="Hepatitis" post="B Vaccine with a Novel Adjuvant. MMWR2018; 67: 455–458.29672472"/>
  <result pre="MMWR2018; 67: 455–458.29672472 116JacksonSLentinoJKoppJ, et al.Immunogenicity of a two-dose investigational" exact="hepatitis" post="B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist"/>
  <result pre="a toll-like receptor 9 agonist adjuvant compared with a licensed" exact="hepatitis" post="B vaccine in adults. Vaccine2018; 36: 668–674.29289383"/>
 </snippets>
</snippetsTree>
